Gastroenterology Guide

Clinical Features

GERD presents with a spectrum of symptoms that can be categorized as esophageal and extra-esophageal manifestations:

Typical (Esophageal) Symptoms

• Heartburn: A burning sensation rising from the lower chest or upper abdomen toward the neck, often worse post-prandially or when lying down. This is the most common symptom, present in 70-85% of patients.
• Regurgitation: The effortless return of gastric contents into the mouth or hypopharynx.
• Dysphagia: Difficulty swallowing. Progressive dysphagia suggests a stricture or development of Barrett’s esophagus with dysplasia.
• Odynophagia: Painful swallowing, suggesting severe inflammation or ulceration.
• Water brash: Sudden filling of the mouth with saliva in response to acid reflux.
• Chest pain: Can mimic angina, important to exclude cardiac causes first.
• Nausea and burping

Atypical (Extra-esophageal) Symptoms

These symptoms have a more complex relationship with GERD and may have multiple etiologies:

• Chronic cough: Particularly nocturnal or post-prandial.
• Laryngeal symptoms: Hoarseness, throat clearing, globus sensation (feeling of something stuck in the throat).
• Dental erosions: Due to repeated exposure to acidic refluxate.
• Asthma: GERD can trigger or worsen asthma symptoms through microaspiration or vagal reflexes.
• Recurrent pneumonia: Due to microaspiration of gastric contents.
• Chronic sinusitis and otitis media: Associated with reflux reaching the nasopharynx.

Symptom Patterns

• Postprandial exacerbation: Symptoms typically worsen after meals, especially large or fatty meals.
• Positional variability: Symptoms often increase when lying down or bending over.
• Nocturnal symptoms: Can cause sleep disturbance and are associated with more severe disease.
• Symptom relief with antacids: A characteristic feature that supports the diagnosis.

Pathophysiology

GERD develops when the normal antireflux barriers are compromised, allowing gastric contents to flow back into the esophagus. Understanding the mechanisms involved is crucial for effective management.

Normal Antireflux Mechanisms

• Lower Esophageal Sphincter (LES): The primary antireflux barrier, maintaining a high-pressure zone between the esophagus and stomach (normal resting pressure: 15-30 mmHg).
• Crural diaphragm: Provides external compression to the LES during inspiration and increases intra-abdominal pressure.
• Angle of His: The acute angle between the esophagus and fundus of the stomach creates a flap valve mechanism.
• Esophageal acid clearance: Normal peristalsis and salivary bicarbonate neutralize acid and clear refluxed material.
• Gastric emptying: Efficient emptying reduces the volume available for reflux.

Mechanisms of GERD Development

1. Transient LES Relaxations (TLESRs): Spontaneous, inappropriate relaxations of the LES unrelated to swallowing. This is the predominant mechanism in most GERD patients.
2. Hypotensive LES: Chronically reduced LES pressure (<10 mmHg) allows reflux during minimal increases in intra-abdominal pressure.
3. Hiatal hernia: Disrupts the synergy between the LES and crural diaphragm, impairs esophageal acid clearance, and creates a reservoir for acid reflux.
4. Impaired esophageal clearance: Weak or ineffective esophageal peristalsis or reduced salivation leads to prolonged acid contact time.
5. Delayed gastric emptying: Increases the volume available for reflux and raises intragastric pressure.

Factors Affecting LES Pressure

Mucosal Injury Mechanisms

Esophageal mucosal damage occurs when the refluxate overcomes mucosal defense mechanisms:

1. Acid and pepsin: Primary caustic agents causing direct mucosal injury.
2. Bile salts and pancreatic enzymes: In duodenogastroesophageal reflux, can synergistically enhance acid-induced damage.
3. Duration of exposure: Longer acid contact time increases injury.
4. Impaired tissue resistance: Reduced bicarbonate secretion, mucus production, or epithelial cell renewal.

Physical Examination

Physical examination is often normal in GERD patients, especially those with non-erosive disease. However, a thorough examination should be performed to rule out other causes of the patient’s symptoms and to identify potential complications.

General Examination

• Vital signs: Usually normal, but check for tachycardia if anemia is present due to chronic blood loss.
• BMI assessment: Obesity (BMI >30) is a significant risk factor for GERD.
• Nutritional status: Weight loss may suggest complications or alternative diagnoses.

Specific Findings

• Oropharyngeal examination:
  • Dental erosions (particularly on the lingual and palatal surfaces of the teeth)
  • Pharyngeal erythema in laryngopharyngeal reflux
• Chest examination:
  • Wheezing or ronchi if reflux-associated asthma is present
  • Signs of aspiration pneumonia in severe cases
• Abdominal examination:
  • Usually normal
  • Epigastric tenderness may be present
  • Check for organomegaly, masses, or other abdominal pathology

Signs of Complications

• Anemia: Pallor, tachycardia if chronic blood loss from erosive esophagitis or Barrett’s-related ulceration
• Esophageal stricture: No specific physical findings, but may present with dysphagia
• Barrett’s esophagus/Esophageal cancer: Usually no specific findings on examination until advanced disease (weight loss, supraclavicular lymphadenopathy)

Remember that normal examination findings do not exclude GERD. The diagnosis is primarily clinical, based on typical symptoms and response to empiric therapy, with investigations reserved for certain scenarios.

Investigations

Most patients with typical GERD symptoms do not require immediate investigations and can be managed with empiric therapy. Investigations are indicated in specific scenarios:

Indications for Investigation

• Alarm or “red flag” symptoms (dysphagia, weight loss, bleeding, anemia)
• Age >55 years with new-onset symptoms
• Symptoms resistant to empiric therapy
• Atypical symptoms where the diagnosis is uncertain
• High-risk patients (family history of Barrett’s or esophageal adenocarcinoma)
• Prior to antireflux surgery

Diagnostic Methods

1. Endoscopy (OGD – Oesophagogastroduodenoscopy)

• Role: Gold standard for evaluating mucosal injury, identifying complications, and ruling out other conditions.
• Findings:
  • Non-erosive reflux disease (NERD): Normal-appearing mucosa (60-70% of GERD patients)
  • Erosive esophagitis: Mucosal breaks classified by Los Angeles (LA) grade A-D
  • Barrett’s esophagus: Salmon-colored mucosa extending above the gastroesophageal junction
  • Complications: Strictures, ulcers, adenocarcinoma
• Limitations: Low sensitivity for GERD diagnosis as most patients have NERD. Day-to-day variability in findings.

2. Ambulatory pH Monitoring

• Role: Gold standard for diagnosing GERD by quantifying esophageal acid exposure.
• Types:
  • 24-hour catheter-based pH monitoring
  • Wireless pH monitoring (48-96 hours)
  • Combined pH-impedance monitoring (detects acid and non-acid reflux)
• Parameters measured:
  • Acid exposure time (AET): Percentage of time pH <4
  • Number of reflux episodes
  • Symptom association probability (SAP) or symptom index (SI)
• Indications: Refractory symptoms, atypical presentations, pre-surgical evaluation

3. Barium Swallow

• Role: Limited for GERD diagnosis, but useful for structural abnormalities.
• Can detect: Hiatal hernia, strictures, large ulcers, abnormal motility
• Limitations: Poor sensitivity and specificity for GERD diagnosis

4. Esophageal Manometry

• Role: Not for primary GERD diagnosis, but to evaluate esophageal motor function.
• Evaluates: LES pressure, esophageal peristalsis, upper esophageal sphincter function
• Indications: Pre-surgical evaluation, dysphagia evaluation, to rule out achalasia or other motor disorders

5. Reflux Monitoring Tests

• Impedance-pH monitoring: Detects all types of reflux (acid and non-acid) by measuring changes in electrical conductivity
• Bravo capsule: Wireless pH monitoring attached to esophageal mucosa, allows extended (48-96h) monitoring

6. Novel Diagnostics

• Narrow-band imaging: Enhanced endoscopic visualization of mucosal patterns
• Confocal laser endomicroscopy: Real-time histological assessment
• Mucosal impedance: Direct measurement of mucosal integrity

7. Laboratory Tests

• Not diagnostic for GERD, but may be performed to rule out complications or alternative diagnoses
• CBC: Check for anemia if chronic blood loss is suspected
• Helicobacter pylori testing: If peptic ulcer disease is a consideration

Management

GERD management follows a stepwise approach, incorporating lifestyle modifications, medication, and in selected cases, surgical intervention. The goals of treatment are to relieve symptoms, heal esophagitis if present, prevent complications, and maintain remission.

1. Lifestyle Modifications

First-line interventions that should be recommended to all GERD patients:

• Dietary adjustments:
  • Avoid trigger foods: Chocolate, caffeine, spicy foods, citrus, tomato-based products, fatty meals
  • Reduce alcohol consumption
  • Eat smaller, more frequent meals
  • Avoid eating within 3 hours of bedtime
• Weight loss: For overweight/obese patients (BMI >25)
• Elevation of head of bed: By 15-20 cm (6-8 inches) using blocks or a wedge pillow (not just extra pillows)
• Smoking cessation: Reduces reflux and improves response to therapy
• Avoid tight clothing: Particularly around the waist
• Modify medication schedule: If medications exacerbating GERD (e.g., NSAIDs, calcium channel blockers)

2. Pharmacological Therapy

A. Acid Suppression

• Proton Pump Inhibitors (PPIs):
  • First-line therapy for most patients
  • Options: omeprazole (20-40mg), lansoprazole (15-30mg), esomeprazole (20-40mg), pantoprazole (20-40mg), rabeprazole (10-20mg)
  • Initial course: Once daily, 30-60 minutes before breakfast, for 4-8 weeks
  • For partial response: Consider twice-daily dosing
  • Side effects: B12 deficiency, hypomagnesemia, C. difficile infections, potential increased risk of fractures with long-term use
• H2-Receptor Antagonists (H2RAs):
  • Second-line therapy or add-on to PPI for nocturnal symptoms
  • Options: ranitidine (150mg), famotidine (20mg), cimetidine (400mg)
  • Less effective than PPIs for healing erosive esophagitis
  • Can be useful for mild, intermittent symptoms
• Antacids:
  • For immediate, short-term symptom relief
  • Not effective for healing or maintenance therapy
  • Options: aluminum/magnesium hydroxide, calcium carbonate

B. Other Medications

• Prokinetics:
  • Metoclopramide, domperidone (limited evidence)
  • Consider when delayed gastric emptying contributes to GERD
  • Side effects limit long-term use
• Alginate-based products (e.g., Gaviscon):
  • Form a raft on top of gastric contents, preventing reflux
  • Useful for mild symptoms or as add-on therapy
• Sucralfate:
  • Mucosal protectant
  • Limited role in GERD management
• Baclofen:
  • GABA-B agonist that reduces TLESRs
  • Not first-line due to side effects (drowsiness, dizziness)
  • Consider in refractory cases

3. Maintenance Therapy

• Stepped-down approach: After symptom control, attempt to use lowest effective dose
• On-demand therapy: For mild, intermittent symptoms
• Continuous therapy: For severe, frequent symptoms, erosive esophagitis, or Barrett’s esophagus

4. Surgical Management

• Laparoscopic Nissen fundoplication:
  • Creating a 360° wrap of the gastric fundus around the lower esophagus
  • Indications: Refractory symptoms despite optimal medical therapy, patients who cannot tolerate medication, large hiatal hernia, or severe regurgitation
  • Complications: Dysphagia, gas-bloat syndrome, inability to vomit, recurrent reflux
• Partial fundoplication:
  • Toupet (270°) or Dor (anterior 180-200°) procedures
  • Less risk of dysphagia but potentially less effective
• Newer endoscopic/minimally invasive procedures:
  • LINX device (magnetic ring around LES)
  • Stretta procedure (radiofrequency energy delivery)
  • TIF (transoral incisionless fundoplication)
  • Generally less effective than traditional surgery

5. Management of Refractory GERD

For patients who do not respond to standard therapy:

1. Confirm diagnosis with pH monitoring or impedance studies
2. Evaluate for alternative diagnoses (eosinophilic esophagitis, achalasia, rumination syndrome)
3. Optimize PPI therapy (twice daily, before meals)
4. Add nighttime H2RA
5. Consider adjunctive therapies (baclofen, alginate, prokinetics)
6. Evaluate for surgical options

Complications

Chronic GERD can lead to several complications if left untreated or inadequately managed. These range from mucosal damage to potentially life-threatening conditions.

Esophageal Complications

1. Erosive Esophagitis

• Inflammation and erosions of esophageal mucosa
• Classified using Los Angeles (LA) Classification:
  • Grade A: One or more mucosal breaks ≤5mm in length
  • Grade B: At least one mucosal break >5mm, but not continuous between tops of two mucosal folds
  • Grade C: Mucosal breaks continuous between tops of ≥2 mucosal folds, but involving <75% of circumference
  • Grade D: Mucosal breaks involving ≥75% of esophageal circumference
• Higher grades associated with more severe symptoms and resistance to therapy

2. Esophageal Stricture

• Narrowing of the esophageal lumen due to fibrosis and scarring
• Results from chronic inflammation and healing cycles
• Presents with progressive dysphagia, initially for solids then liquids
• Treatment: Endoscopic dilation, acid suppression, sometimes stenting

3. Esophageal Ulceration

• Deep mucosal defects extending into submucosa
• Can cause pain, bleeding, or even perforation
• Treatment: Intensive acid suppression, liquid diet initially

4. Barrett’s Esophagus

• Metaplastic change from normal squamous epithelium to specialized intestinal columnar epithelium
• Risk factors: Chronic GERD (>5 years), male sex, age >50, obesity, smoking, family history
• Clinical significance: Premalignant condition with increased risk of esophageal adenocarcinoma
• Surveillance recommendations:
  • No dysplasia: Endoscopy every 3-5 years
  • Low-grade dysplasia: Endoscopy every 6-12 months or endoscopic eradication therapy
  • High-grade dysplasia: Endoscopic eradication therapy
• Management: PPI therapy, endoscopic surveillance, ablative therapies for dysplasia

5. Esophageal Adenocarcinoma

• Most serious complication, arises from Barrett’s esophagus
• Rising incidence in Western countries
• Risk: 0.1-0.3% annual risk of progression from Barrett’s to cancer
• Symptoms: Progressive dysphagia, weight loss, bleeding (often late findings)
• Treatment: Depends on stage – endoscopic resection, surgery, chemoradiation

Extraesophageal Complications

1. Respiratory Complications

• Aspiration pneumonia: Due to large-volume reflux, especially during sleep
• Asthma exacerbation: Reflux can trigger bronchospasm via vagal reflexes or microaspiration
• Chronic cough: Persistent irritation of the laryngeal area
• Pulmonary fibrosis: Repeated microaspiration can lead to interstitial lung disease

2. Otolaryngologic Complications

• Laryngopharyngeal reflux (LPR): Inflammation of the larynx and pharynx
• Chronic laryngitis: Voice changes, hoarseness, globus sensation
• Vocal cord granulomas/ulcers: Due to acid exposure and irritation
• Chronic sinusitis: Association with reflux reaching nasopharynx

3. Dental Complications

• Dental erosions: Loss of tooth enamel due to acid exposure
• Increased caries risk

Flashcards: GERD

Click on each card to reveal the answer.

Clinical Features

The clinical presentation of peptic ulcer disease can range from asymptomatic to life-threatening complications. The classic symptoms and their patterns differ somewhat between gastric and duodenal ulcers.

Typical Symptoms

• Epigastric pain: The hallmark symptom, described as burning, gnawing, or hunger-like discomfort localized to the epigastrium.
• Temporal pattern:
  • Duodenal ulcers: Pain occurs 2-3 hours after meals, often awakens patient at night, and is typically relieved by food or antacids (“hunger pain”).
  • Gastric ulcers: Pain is often exacerbated by food and not reliably relieved by antacids.
• Nausea and vomiting: More common with gastric ulcers.
• Early satiety: Feeling full after eating small amounts.
• Heartburn: May coexist with PUD, especially in proximal gastric ulcers.
• Unexplained weight loss: More concerning in gastric ulcers (raises suspicion for malignancy).

Signs of Complications

• Bleeding: Hematemesis (vomiting of blood or coffee-ground material), melena (black, tarry stools), or hematochezia (bright red blood per rectum in cases of massive bleeding).
• Perforation: Sudden, severe, diffuse abdominal pain that becomes generalized, with board-like rigidity on examination.
• Gastric outlet obstruction: Progressive early satiety, vomiting (often undigested food), bloating, and weight loss.
• Penetration: Persistent pain radiating to the back (pancreatic penetration) or right upper quadrant (hepatic penetration).

Atypical Presentations

• Elderly patients: May present with minimal or no abdominal pain, even with serious complications.
• NSAID users: Up to 50% may be asymptomatic until they develop complications.
• Patients with comorbidities: May have altered pain perception (e.g., diabetic neuropathy).
• Silent ulcers: Discovered incidentally during endoscopy for other reasons.

Physical Examination

Physical examination findings in uncomplicated PUD are often minimal or nonspecific. However, a thorough examination is essential to evaluate for potential complications and to exclude other causes of abdominal pain.

General Examination

• Vital signs: Usually normal in uncomplicated PUD. Tachycardia, hypotension, or postural changes may indicate significant bleeding.
• General appearance: Assess for pallor (anemia), cachexia (malignancy), or signs of distress.
• Hydration status: Particularly important if vomiting is present.

Abdominal Examination

• Inspection: Usually normal; distension may indicate obstruction or perforation.
• Palpation:
  • Epigastric tenderness is the most common finding in uncomplicated PUD.
  • Guarding or rigidity suggests peritoneal inflammation, possibly from perforation.
  • Succussion splash (sloshing sound when shaking the patient) may indicate gastric outlet obstruction.
• Percussion: Loss of liver dullness may suggest free intraperitoneal air from perforation.
• Auscultation: Hyperactive bowel sounds in early obstruction; absent bowel sounds in peritonitis or late obstruction.

Signs of Complications

• Bleeding:
  • Vital sign abnormalities (tachycardia, hypotension)
  • Pallor
  • Digital rectal examination revealing melena
• Perforation:
  • Board-like rigidity of the abdomen
  • Absence of bowel sounds
  • Rebound tenderness and guarding
  • Loss of liver dullness on percussion
• Gastric outlet obstruction:
  • Visible peristalsis
  • Succussion splash
  • Epigastric distension
  • Dehydration signs in advanced cases

Investigations

The diagnosis of PUD requires both the identification of ulcers and determination of their etiology, particularly H. pylori status. Investigations are also directed at identifying complications and excluding malignancy.

Non-invasive Tests

1. H. pylori Testing

• Urea breath test:
  • Sensitivity and specificity >95%
  • Patient ingests 13C or 14C labeled urea, which is hydrolyzed by H. pylori urease
  • False negatives with recent antibiotics, PPIs, or bismuth compounds
• Stool antigen test:
  • Similar accuracy to breath test
  • Convenient for screening and post-treatment confirmation
• Serology (IgG antibodies):
  • Less accurate (80-90% sensitivity and specificity)
  • Remains positive after eradication, so not useful for confirming cure
  • May be useful when other tests are falsely negative due to medication use

2. Blood Tests

• Full blood count: To identify anemia from chronic blood loss or acute bleeding
• Urea and electrolytes: To assess hydration status, especially with vomiting
• Liver function tests: May be deranged in liver disease or biliary obstruction
• Serum gastrin: If Zollinger-Ellison syndrome is suspected (levels typically >1000 pg/mL)
• Coagulation studies: In patients with bleeding or before endoscopy

3. Imaging

• Erect chest X-ray: May show free air under the diaphragm in perforation (sensitivity ~75%)
• Abdominal X-ray: Generally not helpful for diagnosing uncomplicated PUD
• CT abdomen: Useful for complications, especially perforation or penetration
• Barium studies: Largely replaced by endoscopy but may show ulcer craters or strictures

Invasive Tests

1. Upper Gastrointestinal Endoscopy (OGD)

• Gold standard: Allows direct visualization of ulcers and their location
• Biopsy capabilities:
  • Gastric ulcers should always be biopsied to exclude malignancy
  • Antral biopsies for H. pylori testing (rapid urease test, histology, culture)
• Therapeutic potential: Allows intervention for bleeding ulcers
• Classification: Forrest classification for bleeding ulcers to predict rebleeding risk

2. Endoscopic H. pylori Tests

• Rapid urease test (RUT):
  • Detects urease activity in gastric biopsies
  • Quick results (within minutes to hours)
  • False negatives with recent antibiotics, PPIs, or active bleeding
• Histology:
  • Allows visualization of the organism and assessment of mucosal damage
  • High sensitivity and specificity with experienced pathologists
• Culture:
  • Allows antibiotic sensitivity testing
  • Limited by technical difficulty and slow growth

Management

The management of PUD focuses on eradicating causative factors (particularly H. pylori), reducing acid secretion, promoting ulcer healing, and preventing complications.

1. General Measures

• Lifestyle modifications:
  • Smoking cessation (smoking delays ulcer healing and increases recurrence)
  • Alcohol reduction (if excessive)
  • Avoidance of triggering foods (individualized)
• Medication adjustments:
  • Discontinue NSAIDs when possible
  • If NSAIDs must be continued, use the lowest effective dose and consider gastroprotection

2. H. pylori Eradication

First-line therapy usually involves triple therapy for 10-14 days:

• PPI (standard dose twice daily) plus
• Amoxicillin (1g twice daily) plus
• Clarithromycin (500mg twice daily) or Metronidazole (400mg twice daily)

Alternative regimens for areas with high clarithromycin resistance or treatment failure:

• Bismuth quadruple therapy: PPI + Bismuth subcitrate + Tetracycline + Metronidazole
• Levofloxacin triple therapy: PPI + Amoxicillin + Levofloxacin
• Sequential therapy: PPI + Amoxicillin for 5 days, followed by PPI + Clarithromycin + Metronidazole for another 5 days
• Concomitant therapy: PPI + Amoxicillin + Clarithromycin + Metronidazole for 10-14 days

Confirmation of eradication (at least 4 weeks after completing therapy and after stopping PPI for 2 weeks):

• Urea breath test
• Stool antigen test
• Repeat endoscopy only if clinically indicated

3. Acid Suppression

• Proton pump inhibitors (PPIs):
  • First-line for acid suppression
  • Examples: omeprazole 20-40mg, lansoprazole 30mg, esomeprazole 40mg daily
  • Duration: 4-8 weeks for duodenal ulcers, 8-12 weeks for gastric ulcers
• H2-receptor antagonists (H2RAs):
  • Alternative if PPIs not tolerated
  • Examples: ranitidine 150mg twice daily, famotidine 20mg twice daily
  • Less effective than PPIs
• Antacids and alginates:
  • Provide symptomatic relief
  • Not effective for ulcer healing

4. NSAID-Associated Ulcers

• Discontinue NSAIDs if possible
• If NSAIDs must be continued:
  • Switch to COX-2 selective inhibitor (lower GI risk)
  • Add PPI for gastroprotection
  • Consider misoprostol (prostaglandin analog) as an alternative gastroprotective agent
• Test for and eradicate H. pylori if present (provides some protection)

5. Management of Complications

Bleeding

• Resuscitation: IV access, fluid replacement, blood transfusion if needed
• Endoscopic therapy:
  • Injection (epinephrine)
  • Thermal methods (coagulation)
  • Mechanical methods (clips)
  • Often combination therapy is most effective
• Pharmacological therapy: IV PPI (80mg bolus followed by 8mg/h infusion for 72 hours)
• Refractory bleeding: Interventional radiology (embolization) or surgery

Perforation

• Nil by mouth, IV fluids, broad-spectrum antibiotics
• Nasogastric tube to decompress the stomach
• Surgical repair: Typically laparoscopic or open omental patch repair
• Non-operative management: May be considered in select stable patients with contained perforations

Gastric Outlet Obstruction

• Initial management: Nasogastric decompression, fluid and electrolyte correction
• Endoscopic balloon dilation: For fibrotic strictures
• Surgery: For refractory cases (gastrojejunostomy or pyloroplasty)

Complications

Despite advances in treatment, PUD can lead to several serious complications that contribute significantly to its morbidity and mortality.

1. Hemorrhage

• Epidemiology: Most common complication of PUD, accounting for 15-20% of cases
• Risk factors: Age >60, anticoagulant/antiplatelet therapy, NSAID use, prior bleeding history
• Clinical presentation:
  • Hematemesis (vomiting bright red blood or coffee-ground material)
  • Melena (black, tarry stools)
  • Hematochezia (bright red blood per rectum in massive bleeding)
  • Signs of hypovolemia (tachycardia, hypotension, dizziness)
• Forrest classification: Endoscopic classification system that predicts rebleeding risk
  • Class I: Active bleeding (Ia: spurting, Ib: oozing)
  • Class II: Recent bleeding (IIa: visible vessel, IIb: adherent clot, IIc: flat pigmented spot)
  • Class III: Clean base, no active bleeding
• Management:
  • Resuscitation and hemodynamic stabilization
  • Endoscopic therapy for high-risk lesions (Forrest Ia-IIb)
  • IV PPI therapy
  • Interventional radiology or surgery for refractory bleeding

2. Perforation

• Epidemiology: Occurs in 2-10% of PUD cases, with a mortality rate of 10-40%
• Risk factors: NSAID use, smoking, advanced age, H. pylori infection, corticosteroid use
• Clinical presentation:
  • Sudden onset of severe, generalized abdominal pain
  • Board-like rigidity of the abdomen
  • Absent bowel sounds
  • Tachycardia, fever
  • Pneumoperitoneum on imaging (free air under diaphragm)
• Management:
  • Surgical repair (usually laparoscopic or open omental patch)
  • Antibiotics covering enteric gram-negative and anaerobic organisms
  • Fluid resuscitation and correction of electrolyte imbalances
  • Post-operative H. pylori eradication if positive

3. Gastric Outlet Obstruction

• Epidemiology: Occurs in 1-2% of PUD cases, more common with duodenal ulcers
• Pathophysiology:
  • Acute: Edema and inflammation around the pylorus
  • Chronic: Fibrosis and scarring leading to stricture
• Clinical presentation:
  • Progressive early satiety
  • Nausea and vomiting, often of undigested food
  • Weight loss
  • Abdominal bloating and distension
  • Succession splash on examination
• Management:
  • Nasogastric decompression
  • Correction of fluid and electrolyte imbalances
  • PPI therapy and H. pylori eradication if positive
  • Endoscopic balloon dilation
  • Surgical intervention (gastrojejunostomy, pyloroplasty) for refractory cases

4. Penetration

• Definition: Extension of the ulcer through the entire wall into adjacent structures without free perforation
• Common sites:
  • Posterior duodenal ulcers: Penetration into pancreas
  • Anterior gastric ulcers: Penetration into liver
• Clinical presentation:
  • Persistent pain despite medical therapy
  • Pain that radiates to the back (pancreatic penetration)
  • Change in the pain’s character or timing
  • Elevated pancreatic enzymes (amylase, lipase) with pancreatic penetration
• Management:
  • Intensive PPI therapy
  • Surgical intervention may be necessary for refractory cases

5. Gastric Cancer

• Relationship: Gastric ulcers can occasionally be malignant or develop into cancer
• Risk factors: Age >50, weight loss, anorexia, mass on imaging, elevated margins on endoscopy
• Approach:
  • All gastric ulcers should be biopsied (at least 6 samples from different areas)
  • Follow-up endoscopy in 8-12 weeks to confirm healing
  • Non-healing gastric ulcers require repeat biopsies and consideration for surgical resection

Flashcards: Peptic Ulcer Disease

Click on each card to reveal the answer.

Clinical Features

IBD presents with a wide spectrum of intestinal and extraintestinal manifestations, with significant differences between Crohn’s disease and ulcerative colitis.

Intestinal Manifestations

Crohn’s Disease

• Abdominal pain: Commonly right lower quadrant (if terminal ileum involved), often cramping
• Diarrhea: Usually non-bloody, may be voluminous if extensive small bowel involvement
• Weight loss: More common and severe than in UC due to malabsorption
• Perianal disease: Fistulas, abscesses, fissures, skin tags (20-30% of CD patients)
• Intestinal obstruction: Due to strictures or inflammatory masses
• Oral manifestations: Aphthous ulcers, angular cheilitis, granulomatous cheilitis
• Growth failure: In children and adolescents

Ulcerative Colitis

• Bloody diarrhea: Cardinal symptom, often with mucus
• Tenesmus: Urgent sensation to defecate
• Abdominal pain: Usually left-sided or hypogastric, relieved by defecation
• Rectal bleeding: Almost universal
• Nocturnal symptoms: Frequency and urgency
• Weight loss: Less common than in CD, usually with severe disease

Extraintestinal Manifestations (EIMs)

Occur in 25-40% of IBD patients and may precede intestinal symptoms:

Musculoskeletal

• Peripheral arthritis:
  • Type I: Pauciarticular, affects large joints, correlates with intestinal activity
  • Type II: Polyarticular, affects small joints, independent of intestinal activity
• Axial arthropathies:
  • Ankylosing spondylitis (3-5%)
  • Sacroiliitis (10-15%)
• Osteoporosis: Due to malabsorption, inflammation, and steroid use

Dermatological

• Erythema nodosum: Painful red nodules on extensor surfaces, correlates with disease activity
• Pyoderma gangrenosum: Painful ulcerating lesions, often on legs, may be independent of intestinal activity
• Sweet’s syndrome: Acute febrile neutrophilic dermatosis, rare
• Oral aphthous ulcers: More common in CD

Ocular

• Episcleritis: Correlates with intestinal activity
• Uveitis: Can cause permanent visual loss if untreated, independent of intestinal activity
• Conjunctivitis: Relatively common

Hepatobiliary

• Primary sclerosing cholangitis (PSC): More common in UC (5-10%), can lead to cirrhosis and cholangiocarcinoma
• Fatty liver disease: Common
• Cholelithiasis: Increased in CD, especially after ileal resection
• Autoimmune hepatitis: Rare association

Other

• Thromboembolic disease: Increased risk of DVT/PE, especially during flares
• Metabolic bone disease: Osteopenia, osteoporosis
• Anemia: Due to iron deficiency, chronic disease, vitamin B12/folate deficiency, or drug-induced
• Amyloidosis: Secondary, more common in CD

Disease Classification

Crohn’s Disease: Montreal Classification

• Age at diagnosis (A):
  • A1: ≤16 years
  • A2: 17-40 years
  • A3: >40 years
• Location (L):
  • L1: Ileal
  • L2: Colonic
  • L3: Ileocolonic
  • L4: Isolated upper disease (modifier)
• Behavior (B):
  • B1: Non-stricturing, non-penetrating
  • B2: Stricturing
  • B3: Penetrating
  • p: Perianal disease modifier

Ulcerative Colitis: Montreal Classification

• Extent (E):
  • E1: Ulcerative proctitis (rectum only)
  • E2: Left-sided/distal colitis (up to splenic flexure)
  • E3: Extensive colitis/pancolitis (beyond splenic flexure)
• Severity (S):
  • S0: Clinical remission
  • S1: Mild (≤4 stools/day, no systemic symptoms, normal inflammatory markers)
  • S2: Moderate (4-6 stools/day, minimal systemic symptoms)
  • S3: Severe (>6 bloody stools/day, pulse >90 bpm, temperature >37.5°C, hemoglobin <10.5 g/dL, ESR >30 mm/h)

Physical Examination

The physical examination in patients with suspected or known IBD should be comprehensive, as findings can provide crucial information about disease activity, complications, and extraintestinal manifestations.

General Assessment

• Vital signs: Tachycardia, fever, and hypotension may indicate severe disease or complications
• Nutritional status: Assess for cachexia, muscle wasting, and signs of specific nutritional deficiencies
• Hydration status: Skin turgor, mucous membranes, capillary refill
• Growth parameters: Height and weight (particularly important in children and adolescents)

Abdominal Examination

• Inspection:
  • Distension (obstruction, toxic megacolon)
  • Scars from previous surgeries
  • Visible peristalsis (obstruction)
• Auscultation:
  • Hyperactive bowel sounds (early obstruction)
  • Absent/diminished bowel sounds (ileus, peritonitis)
• Palpation:
  • Tenderness: Right lower quadrant in terminal ileal CD, left-sided in distal UC
  • Palpable mass: May suggest abscess, phlegmon, or matted loops in CD
  • Hepatomegaly: Associated with PSC or other hepatobiliary complications
• Percussion: Assess for ascites or organomegaly

Perianal Region

• Inspection: Skin tags, fissures, fistula openings, abscesses
• Digital rectal examination: Assess sphincter tone, tenderness, masses, presence of blood

Extraintestinal Manifestations

• Skin:
  • Erythema nodosum: Tender, red nodules typically on extensor surfaces
  • Pyoderma gangrenosum: Painful ulcerating lesions, often on lower limbs
  • Aphthous ulcers in the mouth
• Joints:
  • Arthritis: Swelling, warmth, tenderness, limited range of motion
  • Sacroiliitis: Tenderness over sacroiliac joints, positive FABER test
  • Ankylosing spondylitis: Reduced spinal mobility, positive Schober’s test
• Eyes:
  • Episcleritis: Painless redness of the episclera
  • Uveitis: Painful red eye with photophobia and visual disturbance
• Hepatobiliary: Jaundice, hepatomegaly, splenomegaly (PSC, autoimmune hepatitis)

Signs of Complications

• Toxic megacolon:
  • Significant abdominal distension
  • Decreased bowel sounds
  • Systemic toxicity (fever, tachycardia, hypotension)
• Intestinal obstruction:
  • Distension
  • High-pitched bowel sounds
  • Visible peristaltic waves
• Perforation:
  • Board-like rigidity
  • Rebound tenderness
  • Absent bowel sounds
  • Signs of septic shock
• Intra-abdominal abscess:
  • Focal tenderness and guarding
  • Palpable mass
  • Fluctuant swelling

Investigations

A combination of laboratory tests, endoscopic procedures, imaging studies, and histopathology is required for the diagnosis, assessment of disease activity, and monitoring of IBD.

Laboratory Investigations

Blood Tests

• Complete blood count:
  • Anemia: Due to iron deficiency, chronic disease, vitamin B12/folate deficiency
  • Leukocytosis: Inflammation, infection, steroid therapy
  • Thrombocytosis: Acute inflammation
• Inflammatory markers:
  • C-reactive protein (CRP): Acute phase reactant, correlates better with CD activity than UC
  • Erythrocyte sedimentation rate (ESR): Less specific, but useful for trend monitoring
  • Fecal calprotectin: Neutrophil-derived protein, excellent marker of intestinal inflammation
• Biochemistry:
  • Albumin: Low in active disease, malnutrition
  • Electrolytes: May be abnormal due to diarrhea (hypokalemia, hypomagnesemia)
  • Liver function tests: To identify hepatobiliary complications or drug toxicity
  • Renal function: Baseline and monitoring during therapy
• Micronutrient status:
  • Iron studies: Ferritin, transferrin saturation
  • Vitamin B12 and folate: Particularly in ileal CD
  • Vitamin D, calcium, magnesium: For bone health
  • Zinc, selenium: May be deficient in chronic disease or malabsorption

Stool Tests

• Fecal calprotectin: Non-invasive marker of intestinal inflammation, correlates with endoscopic activity
• Stool cultures and parasitology: To rule out infectious causes
• Clostridium difficile toxin: Particularly in patients with recent antibiotic exposure or hospitalization
• Fecal occult blood or lactoferrin: Less specific markers of inflammation

Endoscopic Procedures

Ileocolonoscopy

• Gold standard for diagnosis of both CD and UC
• Ulcerative colitis features:
  • Continuous inflammation starting from rectum
  • Erythema, friability, loss of vascular pattern
  • Shallow ulcers, pseudopolyps in severe disease
  • Backwash ileitis may be present in pancolitis
• Crohn’s disease features:
  • Skip lesions (affected areas interspersed with normal mucosa)
  • Aphthous ulcers, deep serpiginous ulcers
  • Cobblestone appearance
  • Strictures, fistula openings
  • Terminal ileum involvement
• Biopsies: Multiple from affected and unaffected areas

Upper GI Endoscopy

• Indicated in CD patients with upper GI symptoms
• May reveal gastroduodenal involvement in 10-15% of CD patients

Capsule Endoscopy

• Useful for evaluating small bowel disease not accessible by conventional endoscopy
• Contraindicated in patients with known or suspected strictures
• May be preceded by patency capsule to reduce risk of retention

Enteroscopy

• Single or double balloon techniques to access the small bowel
• Allows for biopsies and therapeutic interventions

Imaging Studies

Cross-Sectional Imaging

• Magnetic Resonance Enterography (MRE):
  • Preferred modality for small bowel assessment in CD
  • No radiation exposure, ideal for repeated examinations
  • Evaluates mural inflammation, strictures, fistulae, abscesses
• Computed Tomography Enterography (CTE):
  • Alternative to MRE with similar diagnostic accuracy
  • Radiation exposure is a limitation
  • Better for detecting complications (perforation, abscess)
• Abdominal Ultrasound:
  • Non-invasive, radiation-free
  • Useful for bowel wall thickening, abscesses, fistulae
  • Operator-dependent, limited by body habitus and bowel gas

Other Imaging

• Magnetic Resonance Cholangiopancreatography (MRCP): For suspected PSC
• Pelvic MRI: For perianal Crohn’s disease assessment
• Plain Abdominal X-ray: To assess for toxic megacolon, obstruction, perforation
• DEXA scan: For bone mineral density assessment

Histopathology

• Ulcerative colitis features:
  • Mucosal and submucosal inflammation
  • Crypt architectural distortion
  • Crypt abscesses
  • Goblet cell depletion
  • No granulomas
• Crohn’s disease features:
  • Transmural inflammation
  • Skip lesions
  • Non-caseating granulomas (in 50% of cases)
  • Submucosal fibrosis
  • Lymphoid aggregates

Management

Management of IBD requires a multidisciplinary approach involving gastroenterologists, surgeons, specialist nurses, dietitians, and other healthcare professionals. Treatment strategies aim to induce and maintain remission, prevent complications, and improve quality of life.

General Principles

• Individualized approach: Based on disease type, location, severity, complications, and patient factors
• Treat-to-target strategy: Aiming for clinical remission and mucosal healing
• Step-up vs. top-down therapy: Traditional step-up approach vs. early intensive therapy
• Regular monitoring: Clinical assessment, laboratory markers, endoscopy
• Multidisciplinary care: Coordinated approach to address all aspects of the disease

Medical Therapy

5-Aminosalicylates (5-ASA)

• Examples: Mesalazine, sulfasalazine, olsalazine, balsalazide
• Mechanism: Anti-inflammatory effect, exact mechanism unclear
• Indications:
  • UC: First-line for mild-moderate disease, maintenance therapy
  • CD: Limited efficacy, mainly for colonic disease
• Formulations: Oral, topical (suppositories, enemas, foams)
• Side effects: Generally well-tolerated; headache, nausea, rash, paradoxical worsening of colitis (rare)

Corticosteroids

• Examples: Prednisolone, budesonide, hydrocortisone
• Mechanism: Potent anti-inflammatory and immunosuppressive effects
• Indications:
  • Acute flares in both UC and CD
  • Not suitable for maintenance therapy
• Formulations:
  • Systemic: Oral, intravenous (for severe disease)
  • Topical: Enemas, foams, suppositories
  • Budesonide: Lower systemic effects, for ileal/right colonic CD or UC
• Side effects: Cushingoid features, glucose intolerance, hypertension, osteoporosis, psychiatric effects, adrenal suppression

Immunomodulators

• Thiopurines (Azathioprine, 6-Mercaptopurine):
  • Mechanism: Inhibit lymphocyte proliferation
  • Indications: Maintenance therapy, steroid-sparing agents
  • Onset of action: 3-6 months
  • Side effects: Myelosuppression, hepatotoxicity, pancreatitis, increased infection risk, non-melanoma skin cancers
  • Monitoring: Regular FBC, LFTs
• Methotrexate:
  • Mechanism: Inhibits dihydrofolate reductase, anti-inflammatory
  • Indications: CD (less evidence in UC), particularly in those with concurrent arthropathy
  • Administration: Weekly oral or subcutaneous injections
  • Side effects: Hepatotoxicity, pneumonitis, myelosuppression, teratogenicity
  • Monitoring: FBC, LFTs, renal function
• Calcineurin Inhibitors (Cyclosporine, Tacrolimus):
  • Indications: Severe steroid-refractory UC, fistulizing CD
  • Side effects: Renal toxicity, hypertension, neurotoxicity, opportunistic infections
  • Monitoring: Drug levels, renal function, blood pressure

Biologics

• Anti-TNF agents:
  • Examples: Infliximab, adalimumab, golimumab, certolizumab pegol
  • Mechanism: Neutralize tumor necrosis factor alpha (TNF-α)
  • Indications: Moderate-severe CD and UC, fistulizing CD, extraintestinal manifestations
  • Side effects: Infusion/injection reactions, increased infection risk, demyelinating disorders, reactivation of tuberculosis, non-melanoma skin cancers
  • Monitoring: Pre-treatment screening for TB, hepatitis B; regular clinical assessment
• Anti-integrins:
  • Examples: Vedolizumab
  • Mechanism: Blocks α4β7 integrin, preventing lymphocyte trafficking to gut
  • Indications: Moderate-severe CD and UC
  • Side effects: Generally well-tolerated; nasopharyngitis, headache, arthralgia
  • Gut-selective action with fewer systemic side effects
• Anti-IL-12/23 agents:
  • Examples: Ustekinumab
  • Mechanism: Blocks p40 subunit shared by IL-12 and IL-23
  • Indications: Moderate-severe CD and UC
  • Side effects: Generally well-tolerated; infection risk, potential malignancy risk
• JAK inhibitors:
  • Examples: Tofacitinib
  • Mechanism: Inhibits Janus kinase signaling pathway
  • Indications: Moderate-severe UC
  • Side effects: Increased infection risk, herpes zoster, dyslipidemia, potential increased thrombosis risk
  • Administered orally (advantage over injectable biologics)

Antibiotics

• Indications: Perianal disease, bacterial overgrowth, abscesses, postoperative prophylaxis
• Examples: Metronidazole, ciprofloxacin
• Limited role in primary IBD therapy

Nutritional Management

• Exclusive Enteral Nutrition (EEN):
  • First-line therapy for active pediatric CD
  • Formula-based liquid diet for 6-8 weeks
  • Similar efficacy to corticosteroids for luminal CD, without side effects
  • Less effective in adults but may be used in selected cases
• Partial Enteral Nutrition (PEN): Combined with specific food exclusion
• Dietary interventions:
  • Mediterranean diet: Possible benefit
  • Low FODMAP diet: May help with functional symptoms in IBD
  • Specific Carbohydrate Diet, Crohn’s Disease Exclusion Diet: Emerging evidence
• Micronutrient supplementation: Iron, vitamin B12, folate, vitamin D, calcium, zinc as indicated

Surgical Management

Crohn’s Disease

• Indications: Strictures, fistulae, abscesses, perforation, failed medical therapy, dysplasia/cancer
• Approach: Minimally invasive when possible, bowel-conserving (strictureplasty, limited resection)
• Procedures:
  • Ileocecal resection: Most common operation
  • Strictureplasty: Preserves bowel length
  • Segmental colectomy/subtotal colectomy
  • Drainage of abscesses
  • Seton placement, fistulotomy, advancement flaps for perianal disease
• Recurrence: High rate (70-90% endoscopic, 20-40% clinical at 10 years)
• Postoperative prophylaxis: Immunomodulators or biologics in high-risk patients

Ulcerative Colitis

• Indications: Failed medical therapy, toxic megacolon, perforation, massive bleeding, dysplasia/cancer
• Procedures:
  • Total proctocolectomy with permanent ileostomy: Curative, eliminates cancer risk
  • Total proctocolectomy with ileal pouch-anal anastomosis (IPAA): Preserves intestinal continuity
  • Subtotal colectomy with ileorectal anastomosis: Less invasive but leaves diseased rectum
• Complications of IPAA: Pouchitis, small bowel obstruction, sexual dysfunction, fertility issues, fecal incontinence

Management of Specific Scenarios

Acute Severe Ulcerative Colitis

• Definition: ≥6 bloody stools/day plus at least one systemic feature (pulse >90, temperature >37.8°C, Hb <10.5 g/dL, ESR >30 mm/h)
• Management:
  • Hospital admission
  • IV steroids (hydrocortisone 100mg QDS or methylprednisolone 60mg daily)
  • Daily monitoring: Vital signs, abdominal exam, stool frequency
  • Regular bloods: FBC, CRP, electrolytes, albumin
  • Plain abdominal X-ray: To exclude toxic megacolon
  • Early surgical consultation
• Rescue therapy (if failing IV steroids after 3-5 days):
  • Cyclosporine: 2 mg/kg/day IV
  • Infliximab: 5 mg/kg IV as single dose or accelerated induction
  • Early colectomy if no response or clinical deterioration

Fistulizing Crohn’s Disease

• Assessment: MRI pelvis, examination under anesthesia
• Management:
  • Simple fistulae: Antibiotics (metronidazole, ciprofloxacin), surgical drainage of abscesses, fistulotomy if superficial
  • Complex fistulae: Anti-TNF therapy (infliximab, adalimumab), combined with thiopurines
  • Seton placement for drainage
  • Consideration of diverting stoma or proctectomy for severe, refractory disease

Maintenance Therapy

• UC:
  • Mild-moderate: 5-ASA (oral +/- topical)
  • Moderate-severe or 5-ASA failure: Thiopurines, biologics
• CD:
  • Low risk of recurrence: Thiopurines or no therapy
  • High risk of recurrence: Biologics +/- immunomodulator

Complications

IBD can lead to various complications affecting both intestinal and extraintestinal structures. Early recognition and appropriate management are essential to prevent significant morbidity and mortality.

Intestinal Complications

Crohn’s Disease

• Strictures:
  • Fibrotic narrowing of bowel lumen leading to obstruction
  • Symptoms: Cramping abdominal pain, bloating, vomiting
  • Management: Endoscopic balloon dilation, strictureplasty, resection
• Fistulae:
  • Abnormal connections between bowel and other structures
  • Types: Enteroenteric, enterocutaneous, enterovesical, enterovaginal, perianal
  • Management: Medical (antibiotics, biologics), surgical
• Abscesses:
  • Collections of pus, often associated with fistulae
  • Symptoms: Fever, localized pain, mass
  • Management: Antibiotics, percutaneous or surgical drainage
• Perforation:
  • Free perforation less common than in UC
  • Often contained (forming abscesses)
  • Management: Surgical emergency
• Malabsorption:
  • Due to extensive small bowel involvement or resection
  • Can lead to specific deficiencies (B12, fat-soluble vitamins)
• Short bowel syndrome:
  • After extensive small bowel resections
  • Management: Nutritional support, anti-diarrheals, growth factors

Ulcerative Colitis

• Toxic megacolon:
  • Acute dilatation of colon (>6 cm) with systemic toxicity
  • Risk factors: Severe inflammation, hypokalemia, opiates, anticholinergics
  • Management: Nil by mouth, IV fluids, antibiotics, nasogastric decompression, IV steroids, early surgical consultation, colectomy if no improvement or deterioration
• Massive hemorrhage:
  • Rare but potentially life-threatening
  • Management: Resuscitation, correction of coagulopathy, consideration of colectomy
• Perforation:
  • Complication of severe colitis or toxic megacolon
  • High mortality if surgery delayed
  • Management: Emergency colectomy
• Strictures:
  • Less common than in CD
  • Should raise suspicion for malignancy
  • Management: Endoscopic evaluation with biopsies, surgery if malignancy suspected

Malignancy

• Colorectal cancer (CRC):
  • Increased risk in both UC and colonic CD
  • Risk factors: Disease duration (>8-10 years), extent (pancolitis > left-sided > proctitis), severity, primary sclerosing cholangitis, family history of CRC
  • Surveillance: Colonoscopy with chromoendoscopy and targeted biopsies, starting 8-10 years after diagnosis
• Small bowel adenocarcinoma:
  • Rare but increased risk in small bowel CD
  • Often presents late due to nonspecific symptoms
• Cholangiocarcinoma:
  • Associated with PSC in IBD patients
  • Surveillance with liver imaging and CA 19-9
• Lymphoma:
  • Slightly increased risk, particularly with thiopurine therapy
• Skin cancers:
  • Non-melanoma skin cancers with thiopurines
  • Regular skin examinations recommended

Complications of Therapy

• Steroid-related: Osteoporosis, diabetes, hypertension, cataracts, adrenal suppression
• Immunosuppression-related: Increased risk of infections (including opportunistic), malignancies
• Medication-specific toxicities: Hepatotoxicity (thiopurines, methotrexate), nephrotoxicity (5-ASA, calcineurin inhibitors), pancreatitis (thiopurines)
• Surgical complications:
  • Short-term: Anastomotic leak, bleeding, infection
  • Long-term: Adhesions, incisional hernias, short bowel syndrome
  • IPAA-specific: Pouchitis, cuffitis, pouch failure

Psychosocial Complications

• Anxiety and depression: 2-3 times more common in IBD
• Reduced quality of life: Due to symptoms, medication side effects, limitations on daily activities
• Body image issues: Particularly with steroid therapy or stomas
• Educational and occupational impact: Missed school/work days, career limitations
• Sexual dysfunction: Due to disease activity, medications, or surgery
• Financial burden: Treatment costs, lost productivity

Flashcards: Inflammatory Bowel Disease

Click on each card to reveal the answer.

Clinical Features

The clinical presentation of IBS is characterized by a range of gastrointestinal and extraintestinal symptoms. The nature, severity, and pattern of symptoms often fluctuate over time.

Cardinal Symptoms

Abdominal Pain

• Character: Typically cramping, aching, or sharp
• Location: Variable, often in the lower abdomen
• Timing: May be relieved by defecation and exacerbated by eating
• Severity: Ranges from mild discomfort to severe pain

Altered Bowel Habits

• Constipation: Straining, sensation of incomplete evacuation, hard stools
• Diarrhea: Loose or watery stools, urgency, frequency
• Mixed pattern: Alternating constipation and diarrhea
• Passage of mucus: Common in all subtypes

Bloating and Distension

• Subjective sensation of abdominal fullness (bloating)
• Objective increase in abdominal girth (distension)
• Often worse as the day progresses
• Temporarily relieved by passing flatus or stool

Associated Symptoms

Gastrointestinal

• Early satiety
• Nausea (less common)
• Dyspepsia (30-60% of IBS patients)
• Increased flatulence
• Borborygmi (audible bowel sounds)

Extraintestinal

• Genitourinary: Urinary frequency, nocturia, sexual dysfunction
• Gynecological: Dysmenorrhea, dyspareunia (symptom exacerbation during menstruation in women)
• Musculoskeletal: Fibromyalgia, back pain, temporomandibular joint dysfunction
• Neurological: Headaches, fatigue, poor sleep quality
• Psychological: Anxiety, depression, somatization

Symptom Patterns and Triggers

• Meal-related: Postprandial exacerbation of symptoms (pain, bloating, urgent defecation)
• Stress-related: Symptom flares during periods of psychological stress
• Diurnal variation: Symptoms often worse in the morning or after meals
• Food triggers: Common culprits include:
  • FODMAPs (Fermentable Oligo-, Di-, Mono-saccharides, and Polyols)
  • Caffeine, alcohol
  • High-fat foods
  • Spicy foods
  • Dairy products (lactose)

Clinical Course

• Chronic: Typically a lifelong condition with waxing and waning symptoms
• Fluctuating: Periods of exacerbation and remission
• Non-progressive: Does not lead to serious complications or increased mortality
• Impact: Significant effect on quality of life, work productivity, and healthcare utilization

Pathophysiology

IBS is a multifactorial disorder with a complex pathophysiology involving the interplay of various biological, psychological, and social factors. The current understanding centers on the “biopsychosocial model” of IBS.

Key Pathophysiological Mechanisms

1. Visceral Hypersensitivity

• Definition: Heightened perception of visceral stimuli at thresholds that would not cause symptoms in healthy individuals
• Mechanisms:
  • Peripheral sensitization of gut afferent nerves
  • Central sensitization in the spinal cord and brain
  • Altered descending pain modulation
• Clinical relevance: Explains heightened perception of normal physiological stimuli (e.g., gas, intestinal contractions)

2. Altered Gut Motility

• IBS-D: Accelerated intestinal transit, increased high-amplitude propagating contractions
• IBS-C: Delayed transit, reduced propulsive activity
• IBS-M: Variable patterns of altered motility
• Mechanisms: Abnormal enteric nervous system function, altered smooth muscle responsiveness

3. Brain-Gut Axis Dysfunction

• Definition: Bidirectional communication between the central nervous system and the enteric nervous system
• Components:
  • Neural pathways (vagal and spinal afferents)
  • Hypothalamic-pituitary-adrenal (HPA) axis
  • Immune system signaling
  • Gut microbiota influences
• Abnormalities: Altered central processing of visceral signals, heightened stress responsiveness

4. Gut Microbiota Alterations

• Dysbiosis: Altered composition and function of gut microbiota
• Findings in IBS:
  • Reduced microbial diversity
  • Decreased Bifidobacteria and Lactobacilli
  • Increased Firmicutes-to-Bacteroidetes ratio in some studies
  • Altered microbial metabolites (short-chain fatty acids)
• Mechanism: Affects gut immune function, barrier integrity, neurotransmitter production, and motility

5. Immune Activation and Low-Grade Inflammation

• Findings: Increased mast cells, T lymphocytes, and inflammatory mediators in some IBS patients
• Post-infectious IBS: Develops after acute gastroenteritis, with persistent low-grade inflammation
• Consequence: Contributes to increased permeability, visceral hypersensitivity, and altered motility

6. Intestinal Permeability Changes

• Barrier dysfunction: Altered tight junction proteins leading to increased permeability
• Leaky gut: Allows bacterial products and antigens to interact with immune system
• More prominent: In post-infectious IBS and IBS-D

Integrative Model

The biopsychosocial model integrates these pathophysiological mechanisms with psychological and social factors:

• Psychological factors: Stress, anxiety, depression, catastrophizing
• Social factors: Early life experiences, trauma, abuse, social support
• Physiological factors: The mechanisms described above

This integrated approach helps explain the variability in symptom expression, comorbidity with other conditions, and the effectiveness of diverse treatment approaches targeting different aspects of the disorder.

Physical Examination

The physical examination in patients with suspected IBS is typically normal, as IBS is a functional disorder without structural abnormalities. However, a thorough examination is essential to exclude other conditions and to identify any complications.

General Assessment

• Vital signs: Usually normal (fever would suggest alternative diagnosis)
• General appearance: No signs of systemic illness
• Nutritional status: Typically normal (significant weight loss suggests alternative diagnosis)

Abdominal Examination

• Inspection:
  • No visible abnormalities apart from possible bloating/distension
  • No scars (unless from previous unrelated surgeries)
• Auscultation:
  • Normal bowel sounds
  • No bruits or rubs
• Palpation:
  • Mild tenderness common, particularly in the lower abdomen
  • No masses, hepatomegaly, or splenomegaly
  • No involuntary guarding or rebound tenderness
• Percussion: Normal tympany; no ascites or organomegaly

Digital Rectal Examination

• Essential in patients with lower abdominal symptoms or altered bowel habits
• Findings usually normal in IBS
• Allows assessment of:
  • Anal tone and squeeze pressure
  • Tenderness or masses
  • Presence of fecal impaction (in IBS-C)
  • Presence of blood (would suggest alternative diagnosis)

Extraintestinal Examination

• Skin: No rashes or lesions suggestive of inflammatory conditions
• Joints: May have tenderness in patients with comorbid fibromyalgia, but no true arthritis
• Lymph nodes: No lymphadenopathy

Physical Examination Findings That Suggest Alternative Diagnoses

• Fever
• Significant weight loss
• Palpable abdominal mass
• Rectal mass or blood on digital examination
• Abdominal distension with shifting dullness (ascites)
• Organomegaly
• Perianal disease (fissures, fistulae in Crohn’s disease)
• Extraintestinal manifestations suggestive of inflammatory bowel disease (e.g., erythema nodosum, uveitis)

Investigations

The diagnostic approach to IBS involves limited investigations to rule out other conditions rather than to confirm IBS itself. The extent of testing depends on the patient’s age, symptom pattern, and presence of alarm features.

Diagnostic Criteria

IBS is diagnosed using the Rome IV criteria (see Overview section) in the absence of alarm features and with normal baseline investigations.

Limited Testing Approach in Typical Cases

For patients with typical IBS symptoms without alarm features, limited testing is recommended:

Basic Blood Tests

• Full blood count (FBC): To exclude anemia
• C-reactive protein (CRP) or ESR: Inflammatory markers to screen for IBD
• Thyroid function tests (TFTs): Thyroid disorders can present with altered bowel habits
• Celiac serology: Anti-tissue transglutaminase (tTG) antibodies, particularly in IBS-D or IBS-M

Stool Tests

• Fecal calprotectin: To exclude inflammatory bowel disease; normal in IBS
• Stool cultures and ova/parasite examination: In cases of persistent diarrhea
• Clostridium difficile testing: If recent antibiotic use or healthcare exposure

Additional Investigations Based on Subtype or Concerns

IBS with Diarrhea (IBS-D)

• Colonoscopy: In patients >50 years or with alarm features
• Flexible sigmoidoscopy: May be sufficient in younger patients with concerning symptoms
• Bile acid malabsorption tests: SeHCAT scan or trial of bile acid sequestrants if suspected
• Small bowel imaging: If concerns about Crohn’s disease
• Lactose/fructose breath tests: If intolerance suspected
• Small intestinal bacterial overgrowth (SIBO) testing: Hydrogen/methane breath testing if suspected

IBS with Constipation (IBS-C)

• Colonoscopy: In patients >50 years or with alarm features
• Transit time studies: Radio-opaque markers or wireless motility capsule if slow transit suspected
• Anorectal manometry and balloon expulsion test: If dyssynergic defecation suspected
• Defecography: For suspected pelvic floor disorders

Investigations to Exclude When Alarm Features Are Present

• Colonoscopy: Essential with alarm features (rectal bleeding, weight loss, anemia)
• Upper endoscopy: For upper GI symptoms or concerning features
• CT or MRI abdomen/pelvis: For suspected masses, abscesses, or fistulae
• Small bowel imaging: MR enterography, CT enterography, or capsule endoscopy

Conditions to Rule Out

Management

Management of IBS requires a personalized, multimodal approach addressing both physical symptoms and psychosocial factors. Treatment is typically symptom-based and varies according to IBS subtype and predominant symptoms.

General Principles

• Establish therapeutic relationship: Validation of symptoms, education, setting realistic expectations
• Biopsychosocial approach: Address biological, psychological, and social aspects
• Individualized management: Based on predominant symptoms, severity, and impact on quality of life
• Step-wise approach: Begin with lifestyle and dietary modifications, progressing to pharmacological and psychological interventions

Lifestyle and Dietary Interventions

General Dietary Advice

• Regular meal patterns; avoid skipping meals
• Adequate fluid intake (1.5-2L/day, mostly water)
• Moderate alcohol consumption
• Reduce caffeine intake
• Limit intake of spicy foods if they trigger symptoms
• Keep a food diary to identify personal triggers

Low FODMAP Diet

• Definition: Restriction of Fermentable Oligo-, Di-, and Mono-saccharides And Polyols
• Process:
  • Elimination phase (2-6 weeks): Strict avoidance of all high FODMAP foods
  • Reintroduction phase: Systematic challenge with different FODMAP groups
  • Personalization phase: Long-term diet based on individual tolerances
• Effectiveness: 50-80% of IBS patients show symptomatic improvement
• Implementation: Should be guided by a dietitian

Other Dietary Approaches

• Fiber modification:
  • Soluble fiber (e.g., psyllium) may help both IBS-C and IBS-D
  • Insoluble fiber (bran) may worsen symptoms, especially bloating
  • Gradual increase to minimize side effects
• Specific exclusion diets: Based on identified triggers (e.g., lactose, gluten)

Lifestyle Modifications

• Exercise: Regular physical activity (30 minutes most days)
• Stress management: Relaxation techniques, mindfulness, yoga
• Sleep hygiene: Consistent sleep schedule, adequate sleep duration
• Work-life balance: Time management, boundaries

Pharmacological Management

Medications are typically selected based on predominant symptoms:

IBS with Constipation (IBS-C)

• Fiber supplements: Psyllium, ispaghula husk
• Osmotic laxatives: Polyethylene glycol (PEG), lactulose
• Stimulant laxatives: For intermittent use (senna, bisacodyl)
• Chloride channel activators: Lubiprostone
• Guanylate cyclase-C agonists: Linaclotide, plecanatide
• 5-HT4 receptor agonists: Prucalopride

IBS with Diarrhea (IBS-D)

• Antidiarrheals: Loperamide
• Bile acid sequestrants: Cholestyramine, colesevelam
• Mixed opioid agonists-antagonists: Eluxadoline
• 5-HT3 receptor antagonists: Ondansetron, alosetron
• Antibiotics: Rifaximin (for non-constipated IBS)

Abdominal Pain and Bloating

• Antispasmodics:
  • Anticholinergics: Dicyclomine, hyoscine
  • Direct smooth muscle relaxants: Mebeverine, peppermint oil
• Tricyclic antidepressants (TCAs): Low-dose (e.g., amitriptyline 10-30mg at night)
• Selective serotonin reuptake inhibitors (SSRIs): May help with comorbid anxiety
• Probiotics: Consider trial of specific evidence-based strains

Psychological Therapies

• Cognitive-behavioral therapy (CBT): Addresses maladaptive thoughts and coping strategies
• Gut-directed hypnotherapy: Focuses on altering gut function through suggestion
• Mindfulness-based stress reduction: Improves awareness and acceptance of symptoms
• Psychodynamic therapy: For patients with significant psychological comorbidity

Complementary and Alternative Therapies

• Acupuncture: Mixed evidence but may help some patients
• Herbal preparations: Peppermint oil, STW 5 (Iberogast)
• Biofeedback: Particularly useful for pelvic floor dyssynergia

Management of Refractory IBS

• Reassess diagnosis: Consider missed organic disease
• Optimize current therapies: Ensure adequate dosing and duration
• Combination therapy: Multiple agents targeting different mechanisms
• Consider psychological factors: Unaddressed anxiety, depression, trauma
• Multidisciplinary approach: Gastroenterologist, dietitian, psychologist
• Consider clinical trials: For access to novel therapies

Complications

IBS is a functional disorder that does not lead to serious organic complications such as cancer, bleeding, or perforation. However, it can have significant impacts on quality of life and can lead to various psychosocial and functional complications.

Quality of Life Impact

• Physical functioning: Reduced activity levels due to symptoms
• Social functioning: Limited social interactions, avoidance of activities
• Emotional well-being: Frustration, embarrassment, anxiety about symptoms
• Sexual functioning: Reduced sexual activity, dyspareunia
• Sleep disturbance: Difficulties with sleep onset and maintenance

Psychological Complications

• Anxiety disorders: Higher prevalence compared to general population
• Depression: Reactive to chronic symptoms and limitations
• Somatization: Heightened awareness of bodily sensations
• Health anxiety: Fear that symptoms represent serious undiagnosed illness
• Catastrophizing: Exaggerated negative interpretation of symptoms

Occupational and Economic Impact

• Work absenteeism: Increased sick days
• Presenteeism: Reduced productivity while at work
• Career limitations: Avoiding travel or high-stress positions
• Economic burden: Direct medical costs and indirect costs from lost productivity
• Healthcare utilization: Frequent physician visits, investigations, and treatments

Nutritional Considerations

• Dietary restrictions: Self-imposed limited diet may lead to:
  • Potential nutritional deficiencies with overly restrictive diets
  • Social limitations around eating
  • Development of disordered eating patterns

Medication-Related Complications

• Side effects: From chronic medication use
• Dependency: On laxatives or antidiarrheals
• Polypharmacy: Multiple medications for symptom management

Diagnostic and Iatrogenic Complications

• Repeated unnecessary testing: Radiation exposure, procedural risks
• Misdiagnosis: Missing another condition or inappropriately labeling symptoms as IBS
• Nocebo effects: Adverse effects from treatment expectations

Long-term Considerations

• Chronic, relapsing course: Symptoms wax and wane but typically do not resolve completely
• Not progressive: Does not evolve into inflammatory or malignant conditions
• Normal life expectancy: No impact on mortality

Flashcards: Irritable Bowel Syndrome

Click on each card to reveal the answer.

Clinical Features

The clinical presentation of acute pancreatitis ranges from mild symptoms to severe life-threatening illness. The hallmark symptom is acute onset of severe epigastric pain, but presentation can vary based on severity and complications.

Cardinal Symptoms

Abdominal Pain

• Character: Severe, constant, boring or penetrating
• Location: Epigastric or periumbilical, often radiating to the back
• Onset: Typically acute, reaches maximum intensity within minutes to hours
• Exacerbating factors: May worsen in supine position, after eating, or with alcohol
• Relieving factors: May be partially relieved by sitting forward or knees-to-chest position

Nausea and Vomiting

• Present in 80-90% of patients
• Often persistent and not relieved by vomiting
• May cause significant dehydration

Other Common Symptoms

• Fever: Low-grade in mild cases, higher with infected necrosis
• Anorexia: Typically prominent
• Dyspnea: Due to diaphragmatic irritation, pleural effusions, or ARDS
• Jaundice: May occur with biliary obstruction

Physical Examination Findings

General Appearance

• Appears unwell, often in obvious distress
• May be restless, trying to find a comfortable position
• Signs of dehydration may be present

Vital Signs

• Tachycardia: Common due to pain, dehydration, or SIRS
• Hypotension: In severe cases due to third-space fluid losses
• Tachypnea: Due to pain, pleural effusions, or ARDS
• Fever: May be present, especially with infected necrosis

Abdominal Findings

• Tenderness: Epigastric tenderness, often with guarding
• Distension: Due to ileus or ascites
• Decreased bowel sounds: Due to ileus
• Palpable mass: Rarely, may suggest pseudocyst or walled-off necrosis
• Peritoneal signs: Rebound tenderness may be present in severe cases

Signs of Severe Disease

• Grey Turner’s sign: Flank ecchymosis (indicating retroperitoneal hemorrhage)
• Cullen’s sign: Periumbilical ecchymosis (indicating intraperitoneal hemorrhage)
• Fox’s sign: Ecchymosis of the inguinal ligament area
• Respiratory distress: Due to ARDS or pleural effusions
• Altered mental status: Due to hypoxia, electrolyte abnormalities, or organ failure

Clinical Course and Phases

Acute pancreatitis typically progresses through three phases:

• Early phase (1st week): Dominated by systemic inflammatory response syndrome (SIRS) and organ failure
• Middle phase (2nd week): Characterized by local complications (fluid collections, necrosis)
• Late phase (>2 weeks): Risk of infection of necrosis and persistent organ failure

Variations by Etiology

• Gallstone pancreatitis: Often associated with previous biliary colic, may have jaundice
• Alcoholic pancreatitis: History of alcohol abuse, may have signs of chronic liver disease
• Hypertriglyceridemic pancreatitis: May have eruptive xanthomas, lipemia retinalis
• Post-ERCP pancreatitis: Pain develops within 24 hours of the procedure

Pathophysiology

Acute pancreatitis involves a complex cascade of events initiated by pancreatic injury, leading to inappropriate activation of pancreatic enzymes, autodigestion, inflammation, and potential systemic manifestations.

Initiation of Pancreatic Injury

1. Gallstone-Induced Pancreatitis

• Mechanism: Small gallstones (≤5 mm) migrating into the common bile duct
• Processes:
  • Transient obstruction of the ampulla of Vater
  • Bile reflux into pancreatic duct
  • Increased pancreatic duct pressure
  • Disruption of acinar cell function

2. Alcohol-Induced Pancreatitis

• Direct toxicity: Alcohol and its metabolites damage acinar cells
• Indirect effects:
  • Formation of protein plugs in small pancreatic ducts
  • Enhanced secretion of pancreatic enzymes
  • Reduced secretion of protective pancreatic factors
  • Destabilization of lysosomal and zymogen granule membranes

3. Hypertriglyceridemia-Induced Pancreatitis

• Mechanism: Triglyceride levels >1000 mg/dL (11.3 mmol/L)
• Process:
  • Hydrolysis of triglycerides by pancreatic lipase
  • Release of free fatty acids
  • Local cytotoxic effect on acinar cells and vascular endothelium

Pancreatic Autodigestion

• Normal protective mechanisms:
  • Storage of digestive enzymes as inactive proenzymes (zymogens)
  • Segregation of zymogens in granules
  • Presence of enzyme inhibitors (e.g., SPINK1)
  • Acidic pH of acinar cell cytoplasm
• Disruption leads to:
  • Premature activation of trypsinogen to trypsin within acinar cells
  • Trypsin activates other zymogens (phospholipase A2, elastase, carboxypeptidase)
  • Activated enzymes digest cellular components
  • Cell injury and death (necrosis and apoptosis)

Inflammatory Response

• Local inflammation:
  • Release of damage-associated molecular patterns (DAMPs) from injured cells
  • Activation of inflammatory cells (neutrophils, macrophages)
  • Production of pro-inflammatory cytokines (TNF-α, IL-1, IL-6, IL-8)
  • Release of reactive oxygen species and nitric oxide
  • Microcirculatory dysfunction and ischemia
• Systemic inflammation:
  • Systemic inflammatory response syndrome (SIRS)
  • Capillary leak syndrome and third-spacing of fluids
  • Multi-organ dysfunction syndrome (MODS)

Progression to Severe Disease

• Determinants of severity:
  • Extent of pancreatic necrosis
  • Magnitude of inflammatory response
  • Development of organ failure
  • Patient factors (age, comorbidities)
• Mechanisms of organ failure:
  • Respiratory: ARDS due to inflammatory mediators, pleural effusions
  • Cardiovascular: Vasodilation, increased capillary permeability, myocardial depression
  • Renal: Acute kidney injury due to hypovolemia, cytokine-mediated injury
  • Gastrointestinal: Paralytic ileus, stress ulceration, bacterial translocation
  • Hepatic: Cholestasis, hepatocyte dysfunction
  • Metabolic: Hypocalcemia (calcium-soap formation), hyperglycemia
  • Hematologic: Disseminated intravascular coagulation (DIC)

Secondary Infection

• Occurs in 30-70% of patients with pancreatic necrosis
• Peak incidence in 2nd-4th week of illness
• Mechanisms:
  • Bacterial translocation from gut
  • Hematogenous spread
  • Lymphatic spread
• Common organisms: Enteric gram-negative bacilli, Enterococcus species, anaerobes, fungi
• Consequences: Infected necrosis, bacteremia, sepsis, increased mortality

Resolution and Healing

• Mild acute pancreatitis: Resolution of inflammation within days, complete recovery
• Severe acute pancreatitis:
  • Organization of necrotic tissue
  • Formation of walled-off necrosis (after ~4 weeks)
  • Development of pancreatic pseudocysts
  • Potential for long-term pancreatic dysfunction (exocrine/endocrine)

Physical Examination

The physical examination in acute pancreatitis can provide important clues about the severity of disease, potential etiology, and presence of complications. Findings vary widely depending on the severity of disease.

General Appearance and Vital Signs

• General appearance: May range from mild distress to severely ill
• Vital signs:
  • Temperature: Normal or elevated (fever suggests inflammation or infection)
  • Heart rate: Tachycardia common due to pain, dehydration, or SIRS
  • Blood pressure: Hypotension may indicate severe disease with third-spacing or sepsis
  • Respiratory rate: Tachypnea due to pain, pleural effusions, or ARDS
• Hydration status: Assess for signs of dehydration (dry mucous membranes, decreased skin turgor, sunken eyes)

Abdominal Examination

• Inspection:
  • Abdominal distension: Due to ileus, ascites, or fluid collections
  • Ecchymosis: Cullen’s sign (periumbilical), Grey Turner’s sign (flank), or Fox’s sign (inguinal)
  • Respiratory movements: May be shallow due to pain
• Auscultation:
  • Bowel sounds: Often diminished or absent due to ileus
  • Abdominal bruits: May suggest underlying vascular disease
• Palpation:
  • Tenderness: Typically epigastric, may be diffuse in severe cases
  • Guarding: Voluntary or involuntary (suggesting peritoneal inflammation)
  • Rebound tenderness: May be present in severe cases
  • Masses: Rarely palpable (may indicate pseudocyst or walled-off necrosis)
• Percussion:
  • Tympany: Due to ileus
  • Dullness: May be present with ascites
  • Shifting dullness: Suggests ascites

Other Systems Examination

• Respiratory system:
  • Decreased breath sounds at lung bases: Suggests pleural effusions
  • Crackles or wheeze: May indicate ARDS or pulmonary edema
  • Respiratory distress: Suggesting severe disease
• Cardiovascular system:
  • Tachycardia, hypotension: Signs of shock
  • Jugular venous distension: May indicate fluid overload or cardiac dysfunction
• Skin and extremities:
  • Jaundice: Suggesting biliary etiology or significant cholestasis
  • Peripheral edema: May indicate hypoalbuminemia or fluid overload
  • Xanthomas/xanthelasmas: Suggesting hyperlipidemia
  • Spider nevi, palmar erythema: May suggest chronic liver disease (alcoholic etiology)
• Neurological examination:
  • Altered mental status: Due to hypoxia, electrolyte abnormalities, or organ failure
  • Asterixis: May be present with liver or renal failure

Examination Findings Suggesting Etiology

• Gallstone pancreatitis:
  • Right upper quadrant tenderness
  • Murphy’s sign (suggesting cholecystitis)
  • Jaundice (suggesting common bile duct obstruction)
• Alcoholic pancreatitis:
  • Signs of chronic alcohol use (parotid enlargement, muscle wasting, peripheral neuropathy)
  • Signs of chronic liver disease (spider nevi, palmar erythema, gynecomastia)
• Hypertriglyceridemic pancreatitis:
  • Eruptive xanthomas (small yellow papules with erythematous halos)
  • Lipemia retinalis (milky appearance of retinal vessels)
  • Hepatosplenomegaly (suggesting long-standing hyperlipidemia)

Examination Findings Suggesting Severe Disease

• Cullen’s sign: Periumbilical ecchymosis
• Grey Turner’s sign: Flank ecchymosis
• Fox’s sign: Ecchymosis over the inguinal ligament
• Respiratory distress or hypoxemia
• Hypotension or shock
• Altered mental status
• Significant abdominal distension or tenderness
• Diminished or absent bowel sounds

Investigations

Diagnostic investigations in acute pancreatitis serve to establish the diagnosis, determine the etiology, assess severity, and identify complications.

Laboratory Tests

Diagnosis of Acute Pancreatitis

• Serum amylase:
  • Rises within 2-12 hours, returns to normal within 3-5 days
  • Level ≥3 times upper limit of normal (ULN) is diagnostic
  • Sensitivity ~80%, specificity ~85%
  • Other causes of hyperamylasemia: Salivary gland disorders, macroamylasemia, renal failure, gynecological conditions, intestinal diseases
• Serum lipase:
  • Rises within 4-8 hours, remains elevated for 8-14 days
  • Level ≥3 times ULN is diagnostic
  • More specific than amylase (sensitivity ~85%, specificity ~90%)
  • Preferred diagnostic test due to longer elevation and higher specificity

Etiology Determination

• Liver function tests:
  • Elevated ALT (>150 IU/L) has high positive predictive value for gallstone pancreatitis
  • Elevated bilirubin and alkaline phosphatase suggest biliary obstruction
• Serum triglycerides: Levels >1000 mg/dL (11.3 mmol/L) suggest hypertriglyceridemic pancreatitis
• Serum calcium: To evaluate for hypercalcemia
• Blood alcohol level: May support alcoholic etiology
• Drug screen: For suspected drug-induced pancreatitis
• IgG4 levels: If autoimmune pancreatitis suspected

Severity Assessment

• Complete blood count:
  • Elevated WBC common in inflammation
  • Hemoconcentration (hematocrit >44%) suggests severe disease
• Metabolic panel:
  • Elevated BUN/creatinine: Indicate renal impairment or dehydration
  • Hypoalbuminemia: Suggests severe inflammation or chronic disease
  • Hypocalcemia: Due to calcium sequestration in fat necrosis
  • Hyperglycemia: Due to stress response or pancreatic endocrine dysfunction
• Arterial blood gas: For hypoxemia assessment
• C-reactive protein (CRP):
  • Peaks at 48-72 hours
  • Value >150 mg/L at 48 hours predictive of severe disease
• Procalcitonin: Elevated in infected necrosis or systemic infection
• Coagulation profile: To evaluate for DIC or coagulopathy

Imaging Studies

Ultrasonography

• Role:
  • First-line imaging for evaluation of biliary etiology
  • Limited visualization of pancreas due to overlying bowel gas
  • Identifies gallstones (sensitivity ~95%)
  • May show pancreatic enlargement, peripancreatic fluid
  • Can assess for biliary dilatation
• Limitations: Poor visualization of pancreas, operator-dependent

Computed Tomography (CT)

• Role:
  • Gold standard for diagnosis and staging of severe pancreatitis
  • Best performed 72-96 hours after symptom onset (earlier imaging may miss necrosis)
  • Contrast-enhanced CT (CECT) differentiates viable from non-viable pancreas
  • Identifies local complications: Necrosis, fluid collections, pseudocysts
  • Allows grading of severity (CT severity index)
• Indications:
  • Diagnostic uncertainty
  • Failure to improve clinically within 48-72 hours
  • Suspected complications
  • Rapid clinical deterioration
• CT findings:
  • Pancreatic enlargement
  • Peripancreatic inflammation and fat stranding
  • Pancreatic and/or peripancreatic fluid collections
  • Pancreatic necrosis (non-enhancing areas)
  • Extrapancreatic complications (pleural effusions, ascites)

Magnetic Resonance Imaging (MRI)

• Role:
  • Similar diagnostic capability to CT but without radiation
  • Better for biliary tract evaluation (MRCP)
  • More sensitive for detecting early pancreatic necrosis
  • Better characterization of fluid collections
• Limitations: Cost, availability, longer acquisition time, contraindications (e.g., pacemakers)

Magnetic Resonance Cholangiopancreatography (MRCP)

• Role:
  • Non-invasive evaluation of biliary and pancreatic ducts
  • Detection of choledocholithiasis, duct strictures, or anatomic variants
  • Alternative to ERCP for diagnostic purposes

Endoscopic Ultrasound (EUS)

• Role:
  • High sensitivity for detecting small biliary stones or sludge
  • Evaluation of pancreatic parenchyma and fluid collections
  • Allows for fine-needle aspiration of suspicious lesions or fluid collections
• Particularly useful: In recurrent “idiopathic” pancreatitis

Endoscopic Retrograde Cholangiopancreatography (ERCP)

• Role:
  • Both diagnostic and therapeutic
  • Allows removal of bile duct stones
  • Reserved for therapeutic intervention, not primary diagnosis
• Indications:
  • Suspected choledocholithiasis with cholangitis or persistent biliary obstruction
  • Not routinely performed in acute pancreatitis due to risk of worsening pancreatitis

Severity Assessment Tools

• Ranson’s criteria:
  • At admission and at 48 hours
  • Mortality correlates with number of criteria met
• Modified Glasgow criteria: Uses 8 variables measured during first 48 hours
• APACHE II score: Can be calculated at any time, most accurate
• BISAP score: Simple 5-point score calculated within 24 hours
• CT severity index (CTSI): Combines CT grade with extent of necrosis

Management

Management of acute pancreatitis follows a stepwise approach based on severity, with initial supportive care for all patients and additional interventions for those with severe disease or complications.

Initial Management (First 24-48 Hours)

Fluid Resuscitation

• Cornerstone of early management
• Goals:
  • Restore intravascular volume
  • Maintain adequate tissue perfusion
  • Prevent pancreatic necrosis
• Approach:
  • Aggressive early fluid resuscitation: 5-10 mL/kg/hr (250-500 mL/hr) in first 12-24 hours
  • Crystalloids preferred (Lactated Ringer’s solution)
  • Reassess response every 6 hours: Vital signs, urine output, BUN, hematocrit
  • Adjust rate based on response and comorbidities
• Monitoring: Heart rate, blood pressure, urine output (goal >0.5 mL/kg/hr), BUN, hematocrit

Pain Management

• Opioid analgesics:
  • Morphine or fentanyl preferred
  • Titrate to pain control
  • Patient-controlled analgesia (PCA) often effective
• Avoid NSAIDs in severe cases due to risk of acute kidney injury
• Adjunctive measures: Positioning (leaning forward), local heat

Nutritional Support

• Mild pancreatitis:
  • Early oral feeding as tolerated (within 24-48 hours)
  • Low-fat solid diet is safe and does not need to be preceded by clear liquids
• Severe pancreatitis:
  • Enteral nutrition preferred over parenteral
  • Nasojejunal or nasogastric feeding within 24-48 hours if oral intake not possible
  • Parenteral nutrition reserved for those who cannot tolerate enteral feeding

Other Supportive Measures

• Thromboprophylaxis: Low molecular weight heparin in high-risk patients
• Glycemic control: Monitor and treat hyperglycemia
• Correction of electrolyte abnormalities: Especially hypocalcemia
• Oxygen supplementation: As needed to maintain SpO2 >95%

Management Based on Etiology

Gallstone Pancreatitis

• ERCP with sphincterotomy:
  • Indicated in patients with cholangitis or persistent biliary obstruction
  • Should be performed within 24 hours if indicated
  • Not routinely recommended in mild gallstone pancreatitis without cholangitis
• Cholecystectomy:
  • Mild gallstone pancreatitis: During the same admission or within 2 weeks
  • Severe gallstone pancreatitis: Delayed until resolution of inflammation and fluid collections
  • If surgery contraindicated: Consider endoscopic sphincterotomy alone

Alcoholic Pancreatitis

• Alcohol cessation counseling
• Consider thiamine supplementation
• Management of withdrawal symptoms if present

Hypertriglyceridemic Pancreatitis

• Fasting to decrease triglyceride production
• Insulin therapy: Continuous infusion (activates lipoprotein lipase)
• Plasmapheresis: For extremely high triglyceride levels (>2000 mg/dL) or severe clinical course
• Long-term: Diet, fibrates, statins, niacin, omega-3 fatty acids

Drug-Induced Pancreatitis

• Discontinuation of the offending drug
• Avoid reintroduction of the suspected agent

Management of Severe Acute Pancreatitis

Intensive Care Management

• Indications for ICU admission:
  • SIRS or organ failure
  • Hemodynamic instability
  • Respiratory compromise
  • Severe metabolic disturbances
• Organ support:
  • Respiratory: Oxygen therapy, non-invasive or invasive ventilation
  • Cardiovascular: Vasopressors if needed
  • Renal: Continuous renal replacement therapy for acute kidney injury
• Monitoring: Invasive hemodynamic monitoring, continuous vital signs, intake/output

Antibiotic Therapy

• Prophylactic antibiotics: Not recommended routinely
• Indicated for:
  • Infected pancreatic necrosis (confirmed by culture)
  • Extrapancreatic infections (cholangitis, pneumonia, UTI)
  • Consider if strong suspicion of infected necrosis pending confirmation
• Preferred agents: Carbapenems, fluoroquinolones, metronidazole (based on local guidelines)
• Duration: Based on clinical response and source control

Management of Complications

Acute Fluid Collections

• Approach: Conservative, most resolve spontaneously
• Intervention: Only if symptomatic, infected, or enlarging

Pancreatic Pseudocyst

• Approach: Observation if asymptomatic and stable
• Indications for drainage: Symptoms, complications, size >6 cm, increasing size
• Drainage options:
  • Endoscopic: Preferred approach (transgastric or transduodenal)
  • Percutaneous: If endoscopic approach not feasible
  • Surgical: For complex pseudocysts or failed minimally invasive drainage

Pancreatic Necrosis

• Sterile necrosis: Conservative management with supportive care
• Infected necrosis:
  • Initial antibiotic therapy based on culture results
  • Intervention typically delayed until 4 weeks (walled-off necrosis)
  • Step-up approach: Percutaneous drainage first, then minimally invasive necrosectomy if needed
  • Endoscopic necrosectomy: Increasingly preferred approach
  • Open surgical necrosectomy: Reserved for failure of less invasive approaches

Vascular Complications

• Splenic vein thrombosis: Anticoagulation or observation based on risk-benefit
• Pseudoaneurysm: Angiographic embolization
• Hemorrhage: Resuscitation, angiography with embolization, surgery if refractory

Complications

Acute pancreatitis can lead to a range of local and systemic complications that significantly impact morbidity and mortality. Complications are more common in severe acute pancreatitis and can be classified as early or late, and local or systemic.

Local Complications

Acute Peripancreatic Fluid Collections (APFC)

• Definition: Fluid collections without defined wall, occurring in interstitial edematous pancreatitis
• Timing: Within first 4 weeks
• Course: Most resolve spontaneously; some evolve into pseudocysts
• Management: Conservative unless symptomatic, infected, or enlarging

Pancreatic Pseudocyst

• Definition: Encapsulated fluid collection with well-defined wall, containing no solid material
• Timing: >4 weeks after onset of interstitial edematous pancreatitis
• Symptoms: May cause pain, early satiety, gastric outlet or biliary obstruction
• Complications: Infection, rupture, hemorrhage, fistula formation
• Management: Observation if asymptomatic; drainage if symptomatic, >6 cm, or enlarging

Acute Necrotic Collection (ANC)

• Definition: Collection containing variable amounts of fluid and necrotic material, without defined wall
• Timing: Within first 4 weeks of necrotizing pancreatitis
• Location: Intrapancreatic and/or extrapancreatic
• Management: Conservative unless infected or symptomatic

Walled-off Necrosis (WON)

• Definition: Encapsulated collection of necrotic material with well-defined wall
• Timing: >4 weeks after onset of necrotizing pancreatitis
• Complications: Infection, gastric outlet or biliary obstruction, hemorrhage
• Management:
  • Sterile WON: Observation if asymptomatic
  • Infected WON: Antibiotics + drainage/debridement (step-up approach)

Pancreatic Necrosis

• Definition: Nonviable pancreatic parenchyma
• Types:
  • Sterile necrosis: No infection
  • Infected necrosis: Secondary bacterial contamination
• Diagnosis of infection:
  • Clinical deterioration with fever, leukocytosis
  • CT showing gas bubbles within necrosis
  • Positive culture from fine-needle aspiration
• Management:
  • Sterile: Conservative unless symptomatic
  • Infected: Antibiotics + drainage/debridement

Vascular Complications

• Venous thrombosis: Splenic, portal, or mesenteric veins
• Pseudoaneurysm: Commonly affects splenic, gastroduodenal, or pancreaticoduodenal arteries
• Hemorrhage: From pseudoaneurysm rupture or direct vessel erosion
• Compartment syndrome: Increased intra-abdominal pressure compromising organ perfusion

Other Local Complications

• Pancreatic duct disruption: Leads to persistent collections or pancreatic ascites
• Pancreatic fistula: Communication between pancreas and other organs/spaces
• Bowel ischemia/infarction: Due to vascular compromise
• Biliary obstruction: From compression by inflammatory mass or pseudocyst
• Gastric outlet obstruction: Due to duodenal compression

Systemic Complications

Organ Failure

• Respiratory:
  • Acute respiratory distress syndrome (ARDS)
  • Pleural effusions (typically left-sided)
  • Atelectasis
  • Pneumonia
• Cardiovascular:
  • Shock (hypovolemic, distributive)
  • Myocardial depression
  • Pericardial effusion (rare)
• Renal:
  • Acute kidney injury (pre-renal or intrinsic)
  • May require renal replacement therapy
• Gastrointestinal:
  • Paralytic ileus
  • Stress ulceration
  • Gastrointestinal bleeding

Metabolic Complications

• Hypocalcemia: Due to calcium saponification in areas of fat necrosis
• Hyperglycemia: Due to stress response and pancreatic endocrine dysfunction
• Hypertriglyceridemia: May be cause or effect of pancreatitis
• Hypoxemia: Due to pulmonary complications or ARDS

Hematologic Complications

• Disseminated intravascular coagulation (DIC)
• Thrombotic events: DVT, pulmonary embolism
• Hemoconcentration: Due to fluid sequestration

Long-term Complications

• Exocrine pancreatic insufficiency: Especially after extensive necrosis
• Endocrine pancreatic insufficiency: New-onset diabetes mellitus
• Chronic pancreatitis: Progression from acute to chronic in ~10% of cases
• Recurrent acute pancreatitis: If underlying cause not addressed
• Pancreatic cancer: Slightly increased risk after pancreatitis

Mortality Risk Factors

• Persistent organ failure (especially multi-organ failure)
• Infected pancreatic necrosis
• Extensive pancreatic necrosis (>50% of pancreas)
• Advanced age (>65 years)
• Comorbidities (cardiovascular, pulmonary, renal disease)
• Obesity (BMI >30)

Flashcards: Acute Pancreatitis

Click on each card to reveal the answer.

Clinical Features

Chronic pancreatitis presents with a spectrum of symptoms that evolve over time, often progressing from an early painful phase to a later painless phase with exocrine and endocrine insufficiency.

Cardinal Symptoms

Abdominal Pain

• Character: Severe, deep, boring epigastric pain radiating to the back
• Pattern:
  • Early disease: Episodic, acute attacks with pain-free intervals
  • Advanced disease: Continuous, persistent pain or decreased pain due to “burnout”
• Triggers: Often exacerbated by meals (especially fatty foods) and alcohol
• Relief factors: Leaning forward, fasting, narcotic analgesics
• Mechanisms: Increased intraductal pressure, neural inflammation, perineural invasion

Pancreatic Exocrine Insufficiency

• Steatorrhea: Foul-smelling, floating, oily stools
• Threshold: Typically occurs when >90% of pancreatic function is lost
• Features:
  • Weight loss despite normal or increased appetite
  • Fat-soluble vitamin deficiencies (A, D, E, K)
  • Malnutrition (protein-calorie)

Pancreatic Endocrine Insufficiency

• Pancreatogenic diabetes (Type 3c):
  • Develops in 30-50% of patients with long-standing disease
  • Characterized by reduced insulin and glucagon secretion
  • Increased risk of hypoglycemia with insulin therapy
• Brittle diabetes: Difficult to control due to variable insulin sensitivity

Other Clinical Manifestations

• Nausea and vomiting: Common during pain episodes
• Early satiety: Due to delayed gastric emptying or local mass effect
• Jaundice: Due to bile duct stricture (10-30% of patients)
• Duodenal obstruction: From pancreatic head inflammation/fibrosis
• Splenic vein thrombosis: Leading to left-sided portal hypertension and gastric varices
• Ascites: Due to pancreatic duct disruption (pancreatic ascites)
• Pleural effusion: Due to pancreatico-pleural fistula

Disease Progression

Chronic pancreatitis typically follows a progressive course through several phases:

• Initial phase: Recurrent episodes of acute pancreatitis, normal imaging
• Early phase: Intermittent pain, early structural changes on imaging
• Established phase: Persistent structural changes, development of exocrine insufficiency
• Advanced phase: “Burnout,” reduced pain, exocrine and endocrine insufficiency

Special Clinical Subtypes

Autoimmune Pancreatitis (AIP)

• Type 1 (IgG4-related):
  • Diffuse pancreatic enlargement with “sausage-like” appearance
  • Associated with IgG4-related disease in other organs
  • Dramatic response to steroids
• Type 2 (Idiopathic duct-centric):
  • Affects younger patients
  • Often isolated to pancreas
  • May be associated with inflammatory bowel disease

Hereditary Pancreatitis

• Clinical features: Early onset (before age 20), family history
• Inheritance: Autosomal dominant with 80% penetrance
• Significantly increased risk of pancreatic cancer: 40-50% lifetime risk

Tropical Pancreatitis

• Demographics: Young individuals in tropical regions (India, Africa)
• Features: Large pancreatic calcifications, diabetes, early onset
• Etiology: Possibly related to malnutrition, cassava consumption, genetic factors

Pathophysiology

Chronic pancreatitis involves complex pathophysiological mechanisms that lead to progressive pancreatic damage, inflammation, and fibrosis, ultimately resulting in organ dysfunction.

Pathogenetic Mechanisms

1. Toxic-Metabolic Pathway (Alcohol, Smoking)

• Direct toxic effects:
  • Increased oxidative stress in acinar cells
  • Altered metabolism to fatty acid ethyl esters (FAEEs)
  • Mitochondrial dysfunction and energy depletion
  • Enhanced cytokine production and inflammatory response
• Altered secretion:
  • Increased protein concentration in pancreatic juice
  • Reduced bicarbonate secretion and acidification
  • Formation of protein plugs within small ducts
• Smoking effects:
  • Reduced pancreatic blood flow
  • Oxidative stress promotion
  • Toxin accumulation in pancreas

2. Necrosis-Fibrosis Pathway

• Initial necrosis: Repeated episodes of acute inflammation and necrosis
• Stellate cell activation:
  • Quiescent stellate cells activated by cytokines, oxidative stress
  • Transformation to myofibroblast-like phenotype
  • Production of extracellular matrix proteins
• Progressive fibrosis:
  • Replacement of functional parenchyma with fibrous tissue
  • Impaired blood flow and ischemia
  • Ductal distortion and obstruction
• Perineural inflammation: Neural sheath infiltration by immune cells

3. Duct Obstruction Pathway

• Initial obstruction: Protein plugs, strictures, stones, tumors
• Increased intraductal pressure:
  • Ductal epithelial injury
  • Acinar atrophy from back-pressure
• Stone formation:
  • Calcium carbonate precipitation within protein plugs
  • Formation of intraductal stones (calcifications)
  • Further obstruction and damage in a vicious cycle

4. Genetic Mechanisms

• PRSS1 mutations:
  • Increased trypsinogen autoactivation
  • Resistance to protective inhibition
• SPINK1 mutations:
  • Reduced inhibition of activated trypsin
  • Increased susceptibility to pancreatitis
• CFTR mutations:
  • Impaired bicarbonate secretion
  • Acidification of pancreatic juice
  • Protein precipitation within ducts
• CTRC mutations:
  • Defective trypsin degradation
  • Prolonged trypsin activity

5. Autoimmune Mechanism

• Type 1 AIP:
  • IgG4-positive plasma cell infiltration
  • Storiform fibrosis and obliterative phlebitis
  • Systemic inflammatory process
• Type 2 AIP:
  • Granulocytic epithelial lesions (GELs)
  • Neutrophil infiltration of ductal epithelium
  • Minimal IgG4-positive cells

Pathophysiology of Major Complications

Chronic Pain

• Mechanical factors: Increased ductal/parenchymal pressure, pseudocysts
• Neural mechanisms:
  • Perineural inflammation
  • Neural remodeling with increased nociceptive fibers
  • Central sensitization
  • Altered pain processing in central nervous system

Exocrine Insufficiency

• Progressive loss of acinar cells: Replaced by fibrosis
• Reduced enzyme production: Lipase, amylase, proteases
• Defective enzyme delivery: Due to ductal obstruction
• Reduced bicarbonate secretion: Inadequate pH neutralization in duodenum
• Clinical manifestation threshold: Usually when >90% function is lost

Endocrine Insufficiency

• Loss of islet cells: Due to inflammation and fibrosis
• Preferential loss of β-cells: Leading to insulin deficiency
• Reduced incretin effect: Due to exocrine insufficiency
• Insulin resistance: From chronic inflammation and malnutrition
• Complex metabolism: Concomitant deficiency of glucagon and pancreatic polypeptide

Physical Examination

The physical examination in chronic pancreatitis may be unremarkable, especially in early disease, but can reveal important findings in advanced cases or during acute exacerbations.

General Appearance and Vital Signs

• General appearance: May range from normal to cachexic in advanced disease
• Vital signs:
  • Usually normal in stable chronic pancreatitis
  • Fever, tachycardia may indicate acute exacerbation or complications
• Nutritional status: Weight loss, muscle wasting, temporal wasting in advanced disease

Abdominal Examination

• Inspection:
  • Abdominal distension (ascites or pseudocyst)
  • Visible mass (large pseudocyst)
  • Surgical scars from previous interventions
• Palpation:
  • Epigastric tenderness (common finding)
  • Epigastric mass (inflammatory mass, pseudocyst)
  • Hepatomegaly (if associated alcohol-related liver disease)
  • Splenomegaly (if splenic vein thrombosis or portal hypertension)
• Percussion:
  • Usually normal
  • Dullness if ascites present
• Auscultation:
  • Normal bowel sounds
  • Rarely, bruit over splenic artery pseudoaneurysm

Signs of Exocrine Insufficiency

• Malnutrition:
  • Reduced subcutaneous fat
  • Muscle wasting
  • Loose skin
• Vitamin deficiencies:
  • Vitamin A: Night blindness, xerophthalmia
  • Vitamin D: Bone tenderness
  • Vitamin E: Peripheral neuropathy, ataxia
  • Vitamin K: Easy bruising, prolonged bleeding
• Specific findings:
  • Peripheral edema (hypoalbuminemia)
  • Glossitis and angular cheilitis (B vitamin deficiencies)
  • Dermatitis (zinc, essential fatty acid deficiency)

Signs of Endocrine Insufficiency

• Diabetes-related findings:
  • Polyuria, polydipsia (rarely reported by patient)
  • Poor wound healing
  • Peripheral neuropathy

Signs of Complications

• Jaundice: With biliary obstruction
• Portal hypertension:
  • Splenomegaly
  • Caput medusae (collateral vessels around umbilicus)
  • Hematemesis/melena (from gastric varices due to splenic vein thrombosis)
• Pseudocyst-related:
  • Palpable abdominal mass
  • Gastric outlet obstruction symptoms
  • Respiratory compromise (for very large pseudocysts)
• Pancreatic ascites: Shifting dullness, fluid wave

Findings Associated with Etiology

• Alcohol-related:
  • Signs of chronic liver disease (spider nevi, palmar erythema)
  • Dupuytren’s contracture
  • Parotid enlargement
  • Rhinophyma
• Autoimmune pancreatitis:
  • Jaundice
  • Signs of other autoimmune conditions (e.g., sialadenitis, retroperitoneal fibrosis)

Investigations

Diagnosing chronic pancreatitis requires a combination of clinical, laboratory, functional, and imaging studies. Early disease can be challenging to diagnose as structural changes may be minimal.

Laboratory Investigations

Routine Blood Tests

• Complete blood count:
  • Anemia (malnutrition, vitamin B12 deficiency)
  • Leukocytosis (during acute exacerbations)
• Liver function tests:
  • May be normal or show cholestatic pattern if biliary obstruction
  • Elevated in alcohol-related liver disease
• Renal function: To assess hydration status and baseline function
• Serum calcium and magnesium: Often low due to malabsorption
• Blood glucose: To detect diabetes mellitus
• HbA1c: To assess long-term glycemic control

Pancreatic Enzymes

• Serum amylase/lipase:
  • Usually normal or only mildly elevated in chronic pancreatitis
  • May be significantly elevated during acute exacerbations
  • May be low in advanced disease (pancreatic burnout)

Nutritional Parameters

• Serum albumin: May be low due to malnutrition
• Prothrombin time: Prolonged with vitamin K deficiency
• Fat-soluble vitamin levels (A, D, E, K): May be reduced
• Magnesium, zinc, essential fatty acids: Often deficient

Etiology-Specific Investigations

• Serum IgG4: Elevated in type 1 autoimmune pancreatitis
• Genetic testing: For PRSS1, SPINK1, CFTR mutations in appropriate cases
• Sweat chloride test: If cystic fibrosis suspected
• Serum triglycerides: If hypertriglyceridemia suspected
• Serum calcium: To exclude hypercalcemia as cause

Pancreatic Function Tests

Tests for Exocrine Function

• Direct tests:
  • Secretin-stimulated endoscopic pancreatic function test: Gold standard
  • Secretin-cholecystokinin test: Measures bicarbonate and enzyme output
  • Limited availability, invasive, and time-consuming
• Indirect tests:
  • Fecal elastase-1: Most widely used, measures concentration in stool
    • Normal: >200 μg/g
    • Moderate insufficiency: 100-200 μg/g
    • Severe insufficiency: <100 μg/g
  • Fecal chymotrypsin: Alternative to elastase
  • 13C-mixed triglyceride breath test: Measures fat digestion
  • Fecal fat quantification: 72-hour collection, gold standard for steatorrhea
  • Serum trypsinogen: Low in advanced disease

Imaging Studies

Transabdominal Ultrasound

• Role: Initial screening test, limited sensitivity for early disease
• Findings:
  • Pancreatic calcifications
  • Ductal dilatation
  • Parenchymal atrophy
  • Pseudocysts
  • Assessment of complications (biliary obstruction, vascular complications)
• Advantages: Widely available, non-invasive, no radiation
• Limitations: Operator-dependent, bowel gas interference, low sensitivity for early changes

Computed Tomography (CT)

• Role: Primary modality for diagnosis and assessment of complications
• Findings:
  • Parenchymal atrophy
  • Pancreatic calcifications (pathognomonic)
  • Main pancreatic duct dilatation
  • Parenchymal heterogeneity
  • Pseudocysts and fluid collections
  • Vascular complications
• Advantages: Excellent for advanced disease, good for complications
• Limitations: Radiation exposure, less sensitive for early changes
• Cambridge Classification: Based on CT or ERCP findings, grades severity from normal to severe

Magnetic Resonance Imaging (MRI)

• Role:
  • Excellent soft tissue contrast
  • Particularly useful for detecting parenchymal changes
  • Evaluates pancreatic ductal system via MRCP
• Findings:
  • T1-weighted signal changes (decreased) in affected parenchyma
  • Ductal abnormalities
  • Fibrotic changes
• Advantages: No radiation, better than CT for ductal evaluation, better for early changes
• Limitations: Cost, availability, difficulty detecting small calcifications

Magnetic Resonance Cholangiopancreatography (MRCP)

• Role: Non-invasive evaluation of pancreatic and biliary ducts
• Findings:
  • Main pancreatic duct irregularity, dilatation, strictures
  • Side-branch dilatations (“chain of lakes” appearance)
  • Intraductal filling defects (stones)
  • Pancreatic divisum or other anatomic variants
• Advantages: Non-invasive alternative to ERCP, no radiation
• Limitations: Lower spatial resolution than ERCP, no therapeutic options
• Secretin-enhanced MRCP: Improves visualization of ductal anatomy and assesses exocrine reserve

Endoscopic Retrograde Cholangiopancreatography (ERCP)

• Role: Previously gold standard diagnostic test, now primarily therapeutic
• Findings:
  • Main pancreatic duct irregularity, dilatation, strictures
  • Side-branch changes (dilated, irregular)
  • Filling defects (stones)
  • Provides samples for cytology if neoplasm suspected
• Advantages: High sensitivity, allows therapeutic interventions
• Limitations: Invasive, risk of post-ERCP pancreatitis, less commonly used for diagnosis

Endoscopic Ultrasound (EUS)

• Role: Most sensitive imaging modality for early chronic pancreatitis
• Findings (Rosemont criteria):
  • Parenchymal features: Hyperechoic foci, stranding, lobularity, cysts
  • Ductal features: Dilation, irregularity, hyperechoic margins, visible side branches, stones
  • ≥5 criteria: Consistent with chronic pancreatitis
  • 3-4 criteria: Suggestive of chronic pancreatitis
• Advantages: High sensitivity for early changes, allows for FNA if mass lesion
• Limitations: Operator-dependent, invasive, potential for overdiagnosis

Tissue Diagnosis

• EUS-guided fine needle aspiration (FNA):
  • For suspected malignancy
  • For atypical features
  • For suspected autoimmune pancreatitis
• Histological features:
  • Fibrosis
  • Acinar cell loss
  • Chronic inflammatory infiltrate
  • Islet cell sparing until late stages

Management

Management of chronic pancreatitis focuses on alleviating symptoms, addressing malnutrition, managing exocrine and endocrine insufficiency, treating complications, and, when possible, addressing the underlying etiology.

Treatment Goals

• Pain control
• Management of malnutrition and malabsorption
• Treatment of endocrine insufficiency
• Prevention and management of complications
• Improvement in quality of life
• Addressing the underlying etiology (when possible)

Pain Management

Lifestyle Modifications

• Alcohol abstinence: Essential regardless of etiology
• Smoking cessation: Reduces pain and slows progression
• Dietary modifications: Low-fat diet (30-40g fat/day) to reduce pancreatic stimulation
• Small, frequent meals: To minimize postprandial pain

Pharmacological Management

• Analgesic ladder approach:
  • Step 1: Acetaminophen (paracetamol)
  • Step 2: Weak opioids (tramadol)
  • Step 3: Strong opioids (morphine, oxycodone)
• Adjuvant medications:
  • Neuropathic agents: Pregabalin, gabapentin
  • Tricyclic antidepressants: Amitriptyline
  • SNRIs: Duloxetine
• Pancreatic enzyme replacement therapy (PERT): May reduce pain by decreasing CCK stimulation
• Antioxidants: Some evidence for combinations including selenium, vitamin C, vitamin E, methionine

Endoscopic Interventions for Pain

• Pancreatic duct stones:
  • ERCP with stone extraction
  • Extracorporeal shock wave lithotripsy (ESWL) for large stones
  • Pancreatic duct stenting for strictures
• Celiac plexus block/neurolysis:
  • EUS-guided approach preferred
  • Temporary relief (weeks to months)
  • Can be repeated
• Drainage of pseudocysts: If causing pain by mass effect

Surgical Interventions for Pain

• Drainage procedures:
  • Lateral pancreaticojejunostomy (Puestow procedure): For dilated main pancreatic duct (>7mm)
  • Beger procedure: Duodenum-preserving pancreatic head resection
  • Frey procedure: Combines lateral pancreaticojejunostomy with local resection of pancreatic head
• Resection procedures:
  • Pancreaticoduodenectomy (Whipple procedure): For head-dominant disease
  • Distal pancreatectomy: For tail-dominant disease
  • Total pancreatectomy with islet autotransplantation (TPIAT): For intractable pain, preserves beta cell mass
• Indications for surgery:
  • Intractable pain despite maximal medical therapy
  • Suspicion of malignancy
  • Complications not amenable to endoscopic therapy

Management of Exocrine Insufficiency

Pancreatic Enzyme Replacement Therapy (PERT)

• Indications:
  • Steatorrhea (>7g fat/day in stool)
  • Unexplained weight loss
  • Malnutrition despite adequate intake
  • Patients with abnormal pancreatic function tests
• Formulations: Enteric-coated minimicrospherical preparations
• Dosing:
  • Initial: 25,000-40,000 units of lipase with meals, 10,000-25,000 units with snacks
  • Titrate based on symptoms and nutritional parameters
  • Maximum: 10,000 units lipase/kg/day
• Administration:
  • Take with meals and snacks
  • Do not crush or chew capsules
  • Can open capsules for patients unable to swallow
• Optimization strategies:
  • Acid suppression: PPI or H2 blocker if suboptimal response
  • Split dose throughout meal rather than at beginning
  • Increase dose for high-fat meals
• Monitoring:
  • Symptomatic improvement
  • Weight gain/stabilization
  • Normalization of nutritional deficiencies
  • Reduction in steatorrhea

Nutritional Support

• Dietary recommendations:
  • Frequent, small meals
  • Avoid extreme fat restriction (ineffective and potentially harmful)
  • Moderate fat intake (30-40% of calories)
  • Adequate protein intake (1.0-1.5 g/kg/day)
• Micronutrient supplementation:
  • Fat-soluble vitamins (A, D, E, K)
  • Vitamin B12
  • Calcium and magnesium
  • Zinc
  • Iron (if deficient)
• Medium-chain triglycerides (MCTs): Can be absorbed without pancreatic lipase
• Specialized nutritional supplements: If unable to maintain weight

Management of Endocrine Insufficiency

• Diagnose and monitor: Regular blood glucose checks, HbA1c
• Treatment approach:
  • Optimize PERT: Improves incretin release
  • Metformin: First-line if not contraindicated
  • Insulin: Often required due to beta cell loss
    • Higher risk of hypoglycemia due to concomitant alpha cell deficiency
    • Often need lower insulin doses than in type 1 DM
  • Avoid sulfonylureas if possible: Risk of hypoglycemia
  • Consider GLP-1 agonists: Improve glycemic control with lower hypoglycemia risk

Management of Complications

Pseudocysts

• Observation: For asymptomatic pseudocysts <6cm
• Indications for intervention:
  • Symptoms (pain, early satiety, vomiting)
  • Infections
  • Bleeding
  • Biliary or gastric outlet obstruction
  • Size >6cm and persistent >6 weeks
• Drainage options:
  • Endoscopic: Transgastric or transduodenal (preferred if anatomy favorable)
  • Percutaneous: For infected pseudocysts or poor surgical candidates
  • Surgical: Open or laparoscopic drainage to enteric system

Biliary Strictures

• Endoscopic:
  • ERCP with stenting
  • Multiple plastic stents or covered metal stents
  • Serial stent exchange for benign strictures
• Surgical: Biliary bypass if endoscopic management fails

Duodenal Obstruction

• Endoscopic: Duodenal stenting for palliation
• Surgical: Gastrojejunostomy

Splenic Vein Thrombosis

• Monitoring: For development of gastric varices
• Endoscopic: Variceal band ligation or injection if bleeding
• Splenectomy: For recurrent bleeding despite endoscopic management
• Anticoagulation: Not routinely recommended

Pancreatic Fistulae

• Pancreatic duct stenting: To reduce ductal pressure
• Octreotide: To reduce pancreatic secretions
• Surgical management: For persistent fistulae

Etiology-Specific Management

Alcohol-Related

• Alcohol abstinence: Essential to slow progression
• Addiction counseling
• Support groups: AA, etc.

Autoimmune Pancreatitis

• Steroids:
  • Prednisolone 0.6-1 mg/kg/day for 2-4 weeks
  • Gradual taper over 2-3 months
• Maintenance therapy:
  • Low-dose steroids or immunomodulators (azathioprine)
  • For relapsing disease
• Rituximab: For steroid-resistant disease

Hereditary Pancreatitis

• Genetic counseling
• Pancreatic cancer surveillance: Regular imaging starting at age 40-45
• Consider total pancreatectomy with islet autotransplantation: In severe cases

Complications

Chronic pancreatitis can lead to numerous local and systemic complications that significantly impact quality of life, morbidity, and mortality.

Local Complications

Pseudocysts

• Definition: Encapsulated collections of pancreatic juice lacking an epithelial lining
• Incidence: 20-40% of patients with chronic pancreatitis
• Pathogenesis: Disruption of pancreatic duct leading to extravasation of pancreatic juice
• Complications:
  • Infection
  • Rupture (peritonitis)
  • Hemorrhage (erosion into vessels)
  • Obstruction of adjacent organs (stomach, duodenum, bile duct)
  • Fistula formation
• Management: As previously outlined in management section

Pancreatic Duct Stones

• Incidence: 50-90% of patients with long-standing chronic pancreatitis
• Composition: Primarily calcium carbonate
• Consequences:
  • Ductal obstruction
  • Increased intraductal pressure
  • Worsening pain
  • Accelerated parenchymal damage

Biliary Complications

• Biliary stricture: Due to fibrosis around the intrapancreatic portion of the bile duct
• Incidence: 3-46% of patients with chronic pancreatitis
• Consequences:
  • Obstructive jaundice
  • Cholangitis
  • Secondary biliary cirrhosis (in prolonged cases)

Duodenal Obstruction

• Mechanism: Fibrosis or inflammatory mass in the pancreatic head
• Incidence: 1-5% of patients
• Symptoms: Postprandial vomiting, early satiety, weight loss

Pancreatic Fistulae

• Types:
  • Internal: Communication with another viscus (stomach, duodenum, colon)
  • External: Communication with skin surface
  • Pancreatico-pleural: Leading to pleural effusion
  • Pancreatico-peritoneal: Leading to ascites
• Characteristics: Fluid with high amylase content

Vascular Complications

Splenic Vein Thrombosis

• Incidence: 7-20% of patients with chronic pancreatitis
• Mechanism: Direct inflammation and compression of splenic vein
• Consequence: Left-sided (sinistral) portal hypertension
• Clinical significance: Development of gastric varices (risk of bleeding)

Pseudoaneurysm

• Pathogenesis: Enzymatic erosion of arterial walls
• Common vessels: Splenic, gastroduodenal, pancreaticoduodenal arteries
• Complication: Rupture leading to massive hemorrhage
• Management: Angiographic embolization or surgery

Portal Vein Thrombosis

• Less common than splenic vein thrombosis
• Can lead to: Portal hypertension, esophageal varices

Functional Complications

Exocrine Pancreatic Insufficiency (EPI)

• Incidence: 30-50% of patients within 5-10 years of diagnosis
• Pathogenesis: Loss of functional acinar cells, ductal obstruction
• Consequences:
  • Maldigestion, particularly of fats
  • Steatorrhea
  • Weight loss
  • Malnutrition
  • Fat-soluble vitamin deficiencies (A, D, E, K)
  • Trace element deficiencies (zinc, magnesium, selenium)

Endocrine Pancreatic Insufficiency

• Type 3c Diabetes (Pancreatogenic):
  • Develops in up to 80% of patients with long-standing disease
  • Results from loss of islet cells
  • Characterized by deficiency of insulin and glucagon
• Characteristics:
  • “Brittle” diabetes
  • Increased risk of hypoglycemia
  • Reduced glucagon response to hypoglycemia
  • Often requires insulin therapy

Malignancy

Pancreatic Adenocarcinoma

• Risk: Significantly increased in chronic pancreatitis
• Standardized incidence ratio: 14-18 times general population
• Cumulative risk: 4% at 20 years
• Higher risk in:
  • Hereditary pancreatitis (40-55% lifetime risk)
  • Early-onset disease
  • Smoking
  • Long disease duration
• Diagnosis: Challenging due to similar imaging appearance
• Warning signs: Change in pain pattern, unexplained weight loss, new-onset diabetes, jaundice

Psychosocial Complications

• Chronic pain syndrome: Central sensitization, opioid dependence
• Depression and anxiety: 20-60% of patients
• Substance abuse: Especially alcohol and opioids
• Decreased quality of life: Comparable to other chronic pain conditions
• Impaired social functioning: Inability to work, social isolation
• Malnutrition: Affects cognitive function and mood

Other Complications

• Metabolic bone disease: Osteoporosis, osteopenia
• Cardiovascular complications: Increased risk of coronary artery disease
• Increased overall mortality: 3.6-fold higher than the general population
• Recurrent acute pancreatitis: Superimposed on chronic pancreatitis

Flashcards: Chronic Pancreatitis

Click on each card to reveal the answer.

Clinical Features

The clinical manifestations of hepatitis B virus infection vary widely, from asymptomatic infection to fulminant hepatitis. The presentation depends on the patient’s age, immune status, and whether the infection is acute or chronic.

Acute Hepatitis B

Incubation Period

• Typically 60-90 days (range: 30-180 days)
• HBsAg can be detected 30-60 days after exposure
• HBV DNA may be detectable even earlier

Prodromal Phase (Preicteric)

• Constitutional symptoms:
  • Fatigue and malaise
  • Low-grade fever
  • Anorexia and nausea
  • Arthralgia and myalgia
  • Right upper quadrant discomfort
• Duration: Typically 3-10 days

Icteric Phase

• Jaundice: Yellowish discoloration of skin and sclera
• Dark urine: Occurs before visible jaundice
• Clay-colored stools: Due to cholestasis
• Pruritus: Due to bile salt retention
• Hepatomegaly: Tender liver enlargement
• Duration: 1-3 weeks, with gradual improvement

Convalescent Phase

• Gradual resolution of symptoms and jaundice
• Fatigue may persist for weeks to months
• Complete clinical recovery in most adults

Clinical Variations

• Asymptomatic infection: 70% of acute HBV infections in adults
• Anicteric hepatitis: Symptoms without jaundice
• Fulminant hepatitis:
  • Rare (< 1% of acute HBV cases)
  • Rapid progression to liver failure
  • Encephalopathy, coagulopathy, and multiorgan failure
  • High mortality without liver transplantation

Chronic Hepatitis B

Chronic HBV infection evolves through several phases, which may not be sequential and can fluctuate:

Immune Tolerant Phase (HBeAg-positive Chronic Infection)

• Characteristics:
  • HBeAg positive
  • High HBV DNA levels (>107 IU/mL)
  • Normal or minimally elevated ALT
  • Minimal liver inflammation and fibrosis
• Clinical features: Typically asymptomatic
• Duration: Often years to decades, common in perinatally acquired infection
• Infectivity: Highly infectious

Immune Active Phase (HBeAg-positive Chronic Hepatitis)

• Characteristics:
  • HBeAg positive
  • High HBV DNA levels (>104 IU/mL)
  • Elevated ALT
  • Moderate to severe liver inflammation and progressive fibrosis
• Clinical features: May have fatigue, mild hepatomegaly
• Significance: Risk of progression to cirrhosis and HCC

Inactive Carrier Phase (HBeAg-negative Chronic Infection)

• Characteristics:
  • HBeAg negative, anti-HBe positive
  • Low or undetectable HBV DNA (<2000 IU/mL)
  • Normal ALT
  • Minimal liver inflammation and fibrosis
• Clinical features: Typically asymptomatic
• Prognosis: Generally favorable, but requires monitoring

Reactivation Phase (HBeAg-negative Chronic Hepatitis)

• Characteristics:
  • HBeAg negative, anti-HBe positive
  • Fluctuating HBV DNA levels (>2000 IU/mL)
  • Elevated or fluctuating ALT
  • Ongoing liver inflammation and fibrosis
• Mechanism: Viral mutations in precore or core promoter regions
• Clinical features: May have fatigue, fluctuating symptoms
• Significance: Significant risk of progression to cirrhosis and HCC

HBsAg-negative Phase (Occult HBV Infection)

• Characteristics:
  • HBsAg negative
  • Anti-HBc positive, with or without anti-HBs
  • Very low or undetectable HBV DNA
  • Normal ALT
• Clinical relevance: Potential for reactivation with immunosuppression

Extrahepatic Manifestations

• Serum sickness-like syndrome: During acute infection (10-20%)
• Polyarteritis nodosa: Rare but classic association with chronic HBV
• Glomerulonephritis: Membranous or membranoproliferative
• Mixed cryoglobulinemia: Less common than with HCV
• Papular acrodermatitis (Gianotti-Crosti syndrome): In children
• Aplastic anemia: Rare complication

Pathophysiology

The pathophysiology of hepatitis B involves a complex interaction between viral factors and the host immune response, resulting in hepatocellular injury.

Viral Structure and Life Cycle

Virus Structure

• Classification: Hepadnaviridae family, partially double-stranded DNA virus
• Viral particles:
  • Dane particle (complete virion): 42 nm diameter
  • Spherical particles (22 nm) and filamentous forms: excess HBsAg
• Viral components:
  • Envelope (surface): Contains HBsAg
  • Nucleocapsid (core): Contains HBcAg, viral DNA, and polymerase
  • HBeAg: Secreted form of core protein
• Genome: 3.2 kb partially double-stranded circular DNA with four overlapping open reading frames:
  • S gene: Encodes surface proteins (HBsAg)
  • C gene: Encodes core protein (HBcAg) and e protein (HBeAg)
  • P gene: Encodes polymerase with reverse transcriptase activity
  • X gene: Encodes HBx protein (regulatory protein)

Viral Life Cycle

1. Attachment and entry: Virus binds to sodium taurocholate co-transporting polypeptide (NTCP) receptor on hepatocytes
2. Uncoating: Release of viral genome into hepatocyte nucleus
3. Conversion to cccDNA: Relaxed circular DNA is converted to covalently closed circular DNA (cccDNA), which serves as a template for viral transcription
4. Transcription: Production of viral mRNAs
5. Translation: Synthesis of viral proteins
6. Reverse transcription: Pregenomic RNA is reverse transcribed to form viral DNA
7. Assembly: Formation of nucleocapsids
8. Secretion: Release of mature virions and subviral particles

Immune Response and Liver Injury

Innate Immune Response

• Pattern recognition receptors: Detect viral components
• Type I interferons: Induce antiviral state in neighboring cells
• Natural killer (NK) cells: Target infected hepatocytes

Adaptive Immune Response

• Humoral immunity:
  • Antibodies against viral proteins (anti-HBs, anti-HBc, anti-HBe)
  • Anti-HBs is neutralizing and provides protective immunity
• Cell-mediated immunity:
  • CD8+ cytotoxic T lymphocytes (CTLs): Major effectors of viral clearance
  • CD4+ helper T cells: Support CTL and B cell responses

Mechanisms of Liver Injury

• Immune-mediated:
  • CTL recognition and killing of infected hepatocytes
  • Cytokine-mediated inflammation and recruitment of inflammatory cells
  • Bystander damage to uninfected hepatocytes
• Direct cytopathic effects: Limited role in HBV infection

Viral Evasion Strategies

• Immune tolerance: High antigen load leads to T cell exhaustion
• cccDNA persistence: Stable nuclear form resistant to antiviral therapy
• Viral integration: HBV DNA can integrate into host genome
• Viral mutations:
  • Precore mutations: Prevent HBeAg production
  • Core promoter mutations: Reduce HBeAg expression
  • Surface gene mutations: “Escape mutants” evading antibody recognition
  • Polymerase mutations: Confer resistance to antiviral drugs

Pathogenesis of Different Clinical Phases

Acute Infection

• Early phase: High viral replication with minimal immune response
• Symptomatic phase: Robust immune response causing hepatocyte damage
• Resolution: Immune control with viral clearance or containment
• Factors determining outcome: Age, immune competence, viral factors

Chronic Infection

• Immune tolerant phase:
  • High viral replication with minimal immune response
  • Minimal liver damage despite high viral load
  • Common in perinatal infection due to T cell tolerance
• Immune active phase:
  • Partial immune recognition with inflammatory response
  • Progressive liver damage
  • May result in HBeAg seroconversion
• Inactive carrier phase:
  • Immune control with low viral replication
  • Minimal ongoing liver damage
• Reactivation phase:
  • Selection of viral variants (e.g., precore mutants)
  • Resumed viral replication despite HBeAg negativity
  • Renewed liver inflammation and damage

Pathogenesis of Complications

Cirrhosis

• Mechanisms:
  • Repeated cycles of inflammation and repair
  • Activation of hepatic stellate cells
  • Deposition of extracellular matrix
  • Distortion of liver architecture
• Risk factors: HBeAg positivity, high viral load, ALT flares, older age, alcohol use

Hepatocellular Carcinoma (HCC)

• Direct mechanisms:
  • HBV DNA integration into host genome
  • HBx protein: Transactivates cellular genes, interferes with DNA repair
• Indirect mechanisms:
  • Chronic inflammation and regeneration
  • Oxidative stress and DNA damage
  • Epigenetic changes
• Risk factors: Cirrhosis, high viral load, male gender, older age, family history, aflatoxin exposure

Physical Examination

The physical examination findings in patients with hepatitis B vary depending on the disease stage and whether complications are present. Many patients, particularly those with acute hepatitis B or well-controlled chronic infection, may have minimal or no physical findings.

General Appearance and Vital Signs

• Acute hepatitis: May appear ill, fatigued
• Chronic hepatitis: Often normal appearance, especially in early stages
• Advanced liver disease: Cachexia, muscle wasting, signs of malnutrition
• Vital signs:
  • Usually normal in uncomplicated hepatitis
  • Fever may be present in acute infection or superimposed bacterial infection
  • Tachycardia may indicate decompensation or hemorrhage

Skin and Mucous Membranes

• Jaundice:
  • Yellow discoloration of sclera, mucous membranes, and skin
  • Visible when serum bilirubin exceeds 2-3 mg/dL
  • Best assessed in natural light
  • Check sclera (earliest sign), soft palate, and skin
• Spider angiomata: Vascular lesions with central arteriole and radiating vessels, suggestive of chronic liver disease
• Palmar erythema: Redness of the palms, especially the thenar and hypothenar eminences
• Ecchymoses and purpura: Indicating coagulopathy in advanced disease
• Terry’s nails: White nails with distal pink band
• Scratch marks: Due to pruritus in cholestatic presentations

Abdominal Examination

• Liver:
  • Acute hepatitis: Tender hepatomegaly
  • Chronic hepatitis: May be normal or mildly enlarged
  • Cirrhosis: Nodular, firm liver; may be enlarged initially but becomes small in advanced cirrhosis
• Spleen:
  • Splenomegaly in patients with portal hypertension
  • Assess by percussion and palpation
• Ascites:
  • Fluid wave, shifting dullness in decompensated cirrhosis
  • May be subtle (requiring careful examination) or obvious
• Caput medusae: Dilated periumbilical veins due to portosystemic collaterals

Neurological Examination

• Asterixis (“flapping tremor”):
  • Irregular lapses of posture when arms are extended with wrists dorsiflexed
  • Sign of hepatic encephalopathy
• Mental status changes:
  • Ranging from subtle personality changes to confusion and coma
  • Part of the spectrum of hepatic encephalopathy
• Constructional apraxia: Assess with simple drawing tests
• Fetor hepaticus: Sweet, musty breath odor in severe liver dysfunction

Other Findings

• Peripheral edema: Due to hypoalbuminemia and/or portal hypertension
• Gynecomastia: Male breast enlargement due to altered estrogen metabolism
• Testicular atrophy: Due to impaired hormonal function
• Parotid enlargement: May be seen in chronic liver disease
• Dupuytren’s contracture: Palmar fascia fibrosis, associated with chronic liver disease

Examination Findings in Specific Phases

• Acute hepatitis:
  • Jaundice, right upper quadrant tenderness
  • Hepatomegaly is common
  • Generally no signs of chronic liver disease
• Chronic hepatitis (early):
  • Examination often normal
  • Mild hepatomegaly may be present
• Compensated cirrhosis:
  • Firm, nodular liver
  • Splenomegaly
  • Spider angiomata, palmar erythema
  • No signs of decompensation
• Decompensated cirrhosis:
  • Ascites, peripheral edema
  • Asterixis, encephalopathy
  • Muscle wasting, weight loss
  • Prominent collateral veins

Investigations

Diagnostic investigations in hepatitis B aim to establish the diagnosis, determine the stage of infection, assess liver damage, screen for complications, and guide management decisions.

Serological Markers

Hepatitis B Surface Antigen (HBsAg) and Antibody (anti-HBs)

• HBsAg:
  • First serological marker to appear (1-10 weeks after exposure)
  • Indicates active infection (acute or chronic)
  • Persistence >6 months defines chronic infection
• Anti-HBs:
  • Appears after HBsAg clearance
  • Indicates recovery and immunity
  • Also develops after successful vaccination
  • Protective if ≥10 mIU/mL

Hepatitis B Core Antigen (HBcAg) and Antibody (anti-HBc)

• HBcAg: Not routinely detected in serum
• Anti-HBc IgM:
  • Indicates acute infection
  • Usually detectable for 6 months after acute infection
  • May be positive during flares of chronic infection
• Anti-HBc IgG:
  • Persists for life after infection
  • Present in both resolved and chronic infection

Hepatitis B e Antigen (HBeAg) and Antibody (anti-HBe)

• HBeAg:
  • Marker of high viral replication and infectivity
  • Present in acute infection and some phases of chronic infection
• Anti-HBe:
  • Appears after HBeAg clearance
  • Usually indicates lower viral replication
  • But may be present with high viral replication in precore/core promoter mutants

Interpretation of Serological Profiles

Virological Assays

HBV DNA Quantification

• Methods: Real-time PCR (most sensitive)
• Uses:
  • Determines level of viral replication
  • Helps identify disease phase
  • Guides treatment decisions
  • Monitors response to therapy
  • Detects viral breakthrough during treatment
• Interpretation:
  • Reported in IU/mL
  • Detection limit with sensitive assays: 10-15 IU/mL
  • High levels (>107 IU/mL): Typically seen in immune tolerant phase
  • Intermediate levels (104-107 IU/mL): Immune active phase
  • Low levels (<2000 IU/mL): Inactive carrier state

HBV Genotyping

• Genotypes: A through J based on >8% genomic difference
• Clinical relevance:
  • Different geographical distribution
  • May influence disease progression and treatment response
  • Genotype A and B: Better response to interferon therapy
  • Genotype C and D: Higher risk of HCC
• Not routinely performed in clinical practice

Resistance Testing

• Indications: Viral breakthrough during antiviral therapy
• Methods: Direct sequencing, line probe assays
• Common mutations: rtM204V/I (lamivudine, telbivudine), rtA181T/V, rtN236T (adefovir)

Liver Function Tests

• Aminotransferases (ALT, AST):
  • Markers of hepatocellular injury
  • ALT more specific for liver damage than AST
  • May be markedly elevated in acute hepatitis (often >1000 U/L)
  • Variable in chronic hepatitis
  • May normalize in advanced cirrhosis
• Bilirubin:
  • Elevated in acute hepatitis with jaundice
  • Persistently elevated in decompensated cirrhosis
  • Direct (conjugated) fraction predominates
• Alkaline phosphatase:
  • Usually mildly elevated in hepatitis
  • Marked elevation suggests cholestatic pattern
• Gamma-glutamyl transferase (GGT):
  • Another marker of cholestasis
  • Less specific than alkaline phosphatase
• Albumin:
  • Measure of synthetic function
  • Decreased in chronic liver disease
  • Important prognostic indicator
• Prothrombin time (PT)/INR:
  • Also reflects synthetic function
  • Prolonged in severe acute hepatitis and cirrhosis
  • Useful for prognosis and severity assessment

Imaging Studies

Ultrasound

• Role:
  • First-line imaging study
  • Evaluates liver parenchyma, size, and echogenicity
  • Screens for HCC and portal hypertension
  • Detects ascites
• Findings:
  • Acute hepatitis: Normal or hepatomegaly with decreased echogenicity
  • Chronic hepatitis: May be normal or show increased echogenicity
  • Cirrhosis: Nodular surface, heterogeneous echotexture, small liver size
  • Portal hypertension: Splenomegaly, dilated portal vein, collaterals

Computed Tomography (CT)

• Role:
  • Better characterization of liver lesions
  • Evaluates HCC (enhancement patterns)
  • Detects complications (ascites, varices)
• Types:
  • Contrast-enhanced: Multiple phases (arterial, portal venous, delayed)
  • Non-contrast: Limited value except for identifying calcifications

Magnetic Resonance Imaging (MRI)

• Role:
  • Superior for characterizing liver lesions
  • Gold standard for HCC diagnosis
  • Evaluates iron deposition, fat content
  • Liver-specific contrast agents (e.g., gadoxetic acid) enhance detection
• Limitations: Cost, availability, contraindications (e.g., pacemakers)

Transient Elastography (FibroScan)

• Principle: Measures liver stiffness using ultrasound elastography
• Role:
  • Non-invasive assessment of liver fibrosis
  • Monitoring fibrosis progression/regression
  • Ranges: F0-F1: <7 kPa, F2: 7-9 kPa, F3: 9-12 kPa, F4: >12 kPa
• Limitations: Obesity, ascites, acute inflammation

Liver Biopsy

• Role:
  • Assesses inflammation grade and fibrosis stage
  • Excludes other causes of liver disease
  • Less frequently performed with improved non-invasive tests
• Indications:
  • Uncertain diagnosis
  • Discordant non-invasive tests
  • Suspected co-existing liver disease
  • Guiding treatment decisions in selected cases
• Histological findings:
  • Acute hepatitis: Lobular disarray, ballooning degeneration, acidophil bodies
  • Chronic hepatitis: Portal/periportal inflammation, interface hepatitis
  • Cirrhosis: Nodule formation, fibrous septa
  • “Ground glass” hepatocytes (HBsAg accumulation)
• Scoring systems: METAVIR, Ishak, Knodell

Complications

Hepatitis B virus infection can lead to various acute and chronic complications, with significant morbidity and mortality. The risk and nature of complications depend on the phase of infection, patient factors, and virus-related characteristics.

Acute Complications

Acute Liver Failure (Fulminant Hepatitis)

• Incidence: <1% of acute HBV infections
• Definition: Development of hepatic encephalopathy and coagulopathy within 8 weeks of onset in patients without pre-existing liver disease
• Risk factors:
  • Co-infection with hepatitis D virus
  • Pre-existing liver disease
  • Older age
  • Excessive alcohol consumption
• Clinical features:
  • Jaundice progressing to encephalopathy
  • Coagulopathy (INR >1.5)
  • Renal failure
  • Hypoglycemia
  • Metabolic acidosis
  • Multi-organ failure
• Management:
  • Transfer to liver transplant center
  • Intensive supportive care
  • Antiviral therapy (tenofovir or entecavir)
  • Monitoring for complications (cerebral edema, infections)
  • Liver transplantation if poor prognostic indicators
• Prognosis:
  • Mortality 60-80% without liver transplantation
  • Better prognosis for HBV-related acute liver failure than other causes

Acute Kidney Injury

• Mechanisms:
  • Immune complex-mediated glomerulonephritis
  • Direct cytopathic effect
  • Hepatorenal syndrome in severe cases
• Presentation: Proteinuria, hematuria, decreased urine output
• Management: Supportive, treat underlying HBV

Chronic Complications

Cirrhosis

• Incidence: 15-40% of chronically infected patients over lifetime
• Risk factors:
  • Duration of infection
  • High viral load
  • HBeAg positivity
  • Elevated ALT
  • Coinfections (HCV, HIV, HDV)
  • Male gender
  • Older age at acquisition
  • Alcohol consumption
  • Genetic factors
• Compensated cirrhosis:
  • Often asymptomatic
  • Detected by imaging or fibrosis assessment
  • Preserved liver function
• Decompensated cirrhosis:
  • Ascites
  • Variceal bleeding
  • Hepatic encephalopathy
  • Jaundice
  • Coagulopathy
  • Hepatorenal syndrome
  • Spontaneous bacterial peritonitis
• Management:
  • Antiviral therapy regardless of DNA levels or ALT
  • Standard management of cirrhosis complications
  • Liver transplantation for decompensated disease

Hepatocellular Carcinoma (HCC)

• Incidence:
  • 2-8% annual risk in cirrhotic HBV patients
  • 0.1-0.4% annual risk in non-cirrhotic HBV carriers
• Risk factors:
  • Cirrhosis (strongest predictor)
  • Male gender
  • Age >40 years
  • Family history of HCC
  • High viral load
  • HBeAg positivity
  • Genotype C (vs. B)
  • Core promoter mutations
  • Coinfections (HCV, HDV, HIV)
  • Aflatoxin exposure
  • Alcohol consumption
• Surveillance:
  • Ultrasound ± alpha-fetoprotein every 6 months in high-risk patients
  • High-risk groups: Cirrhosis, Asian males >40, Asian females >50, Africans >20, family history
• Management:
  • Potentially curative: Resection, ablation, transplantation (for early-stage disease)
  • Palliative: Transarterial chemoembolization, radioembolization, systemic therapy
• Prevention:
  • Effective antiviral therapy reduces but does not eliminate HCC risk
  • Continued surveillance necessary despite viral suppression

Extrahepatic Complications

Renal Manifestations

• Membranous nephropathy:
  • Most common form of HBV-associated nephropathy
  • Immune complex deposition in glomerular basement membrane
  • Presents with proteinuria, often nephrotic syndrome
• Membranoproliferative glomerulonephritis:
  • Mixed cryoglobulinemia may be present
  • Hematuria, proteinuria, hypertension
• Management: Antiviral therapy, with potential improvement of renal disease

Polyarteritis Nodosa (PAN)

• Association: 30% of PAN cases associated with HBV (declining with decreased HBV prevalence)
• Pathogenesis: Immune complex deposition in medium-sized vessels
• Clinical features:
  • Systemic vasculitis
  • Fever, weight loss
  • Skin lesions (purpura, livedo reticularis)
  • Mononeuritis multiplex
  • Hypertension
  • Abdominal pain (mesenteric ischemia)
  • Renal involvement
• Management: Antiviral therapy, often combined with short-term immunosuppression

Other Extrahepatic Manifestations

• Mixed cryoglobulinemia: Purpura, arthralgia, weakness
• Serum sickness-like syndrome: During acute infection, with rash, arthralgia, fever
• Papular acrodermatitis (Gianotti-Crosti syndrome): In children
• Aplastic anemia: Rare but severe complication
• Peripheral neuropathy: May be manifestation of vasculitis
• Myocarditis: Rarely reported

Treatment-Related Complications

• Interferon-related:
  • Flu-like symptoms
  • Fatigue, depression, irritability
  • Cytopenias
  • Thyroid dysfunction
  • Exacerbation of autoimmune disorders
• Nucleos(t)ide analogues:
  • Lactic acidosis (rare)
  • Tenofovir disoproxil fumarate: Renal impairment, Fanconi syndrome, decreased bone mineral density
  • Entecavir: Few adverse effects
  • Viral resistance (especially with older agents)

Mortality Risk

• Acute infection: <1% mortality
• Chronic infection: 15-25% die from complications of cirrhosis or HCC
• Annual mortality:
  • Compensated cirrhosis: 5%
  • Decompensated cirrhosis: 20-25%
  • HCC: Median survival <1 year without treatment

Flashcards: Hepatitis B

Click on each card to reveal the answer.

Clinical Features

The clinical presentation of hepatitis C infection varies widely from asymptomatic disease to severe hepatic and extrahepatic manifestations. Most patients remain asymptomatic until advanced liver disease develops.

Acute Hepatitis C

Incubation Period

• Typically 2-12 weeks (average 6-7 weeks)
• HCV RNA can be detected 1-2 weeks after exposure
• Anti-HCV antibodies develop 8-12 weeks after infection

Clinical Presentation

• Asymptomatic: 70-85% of acute infections
• Symptomatic: 15-30% with mild to moderate symptoms
  • Fatigue
  • Malaise
  • Right upper quadrant discomfort
  • Nausea and decreased appetite
  • Low-grade fever
  • Arthralgias and myalgias
  • Mild jaundice (less common than in hepatitis A or B)
• Duration: Symptoms typically last 2-12 weeks
• Fulminant hepatic failure: Extremely rare in acute HCV

Laboratory Findings

• ALT/AST elevation: Usually 10-20 times upper limit of normal
• Bilirubin: Normal or mildly elevated
• HCV RNA: Detectable early (1-2 weeks post-exposure)
• Anti-HCV antibodies: Develop later (8-12 weeks)

Chronic Hepatitis C

Clinical Presentation

• Asymptomatic phase: Majority of patients have no symptoms for decades
  • Often diagnosed incidentally on routine blood tests
  • May be detected during blood donation screening
• Non-specific symptoms: If present
  • Fatigue (most common)
  • Mild right upper quadrant discomfort
  • Nausea
  • Poor appetite
  • Arthralgias and myalgias
  • Difficulty concentrating (“brain fog”)
  • Depression
• Advanced liver disease: Symptoms develop with progression to cirrhosis
  • Jaundice
  • Ascites
  • Peripheral edema
  • Hepatic encephalopathy
  • Gastrointestinal bleeding from varices

Laboratory Findings

• ALT/AST: Fluctuating levels, often normal or mildly elevated
• HCV RNA: Persistently detectable
• Anti-HCV antibodies: Positive
• Liver synthetic function: Normal until advanced disease (albumin, INR)
• Platelets: May decrease with progression to cirrhosis

Extrahepatic Manifestations

Occur in 40-70% of patients with chronic HCV infection

Hematologic Manifestations

• Mixed cryoglobulinemia:
  • Most common extrahepatic manifestation (35-55% have detectable cryoglobulins)
  • Symptomatic in 5-10% of patients
  • Clinical features: palpable purpura, arthralgias, weakness, neuropathy, glomerulonephritis
• B-cell non-Hodgkin lymphoma: Increased risk, particularly in those with cryoglobulinemia
• Immune thrombocytopenia: Autoimmune destruction of platelets

Renal Manifestations

• Membranoproliferative glomerulonephritis: Usually associated with cryoglobulinemia
• Membranous nephropathy: Less common
• Proteinuria, hematuria, renal insufficiency

Dermatologic Manifestations

• Palpable purpura: Due to cryoglobulinemic vasculitis
• Porphyria cutanea tarda: Photosensitive vesicular rash, skin fragility
• Lichen planus: Pruritic, purple, polygonal papules
• Necrolytic acral erythema: Rare cutaneous marker

Endocrine/Metabolic Manifestations

• Type 2 diabetes mellitus: Increased prevalence and poorer glycemic control
• Insulin resistance: Common even without diabetes
• Thyroid disorders: Both hypothyroidism and hyperthyroidism

Neuropsychiatric Manifestations

• Fatigue and cognitive impairment: Independent of liver disease severity
• Depression: Higher prevalence than general population
• Peripheral neuropathy: Sensory or sensorimotor

Other Manifestations

• Sicca syndrome: Dry eyes and mouth
• Arthralgia/arthritis: Non-erosive joint inflammation
• Myalgia: Diffuse muscle pain
• Cardiovascular disease: Possible increased risk

Pathophysiology

The pathophysiology of hepatitis C involves complex viral-host interactions leading to hepatic inflammation, fibrosis, and extrahepatic manifestations. Understanding these mechanisms is crucial for developing therapeutic strategies.

Viral Structure and Life Cycle

Virus Structure

• Classification: Flaviviridae family, Hepacivirus genus
• Structure: Enveloped, single-stranded, positive-sense RNA virus
• Genome: ~9.6 kb encoding a single polyprotein of ~3,000 amino acids
• Viral proteins:
  • Structural proteins: Core (C), envelope glycoproteins (E1, E2)
  • Non-structural proteins: NS2, NS3, NS4A, NS4B, NS5A, NS5B (targets for direct-acting antivirals)
• Genetic heterogeneity: High mutation rate leading to significant diversity
  • 8 major genotypes (1-8) with multiple subtypes
  • Multiple quasispecies within an infected individual

Viral Life Cycle

1. Attachment and entry:
   • HCV particles bind to receptors on hepatocyte surface including CD81, SR-B1, claudin-1, occludin
   • Entry via clathrin-mediated endocytosis
2. Uncoating: Release of viral RNA into cytoplasm
3. Translation: Viral RNA translated into a single polyprotein
4. Polyprotein processing: Cleaved by viral and host proteases into individual proteins
5. RNA replication:
   • Formation of membrane-associated replication complex (“membranous web”)
   • RNA-dependent RNA polymerase (NS5B) synthesizes negative-strand RNA
   • Negative-strand template used to produce positive-strand RNA
6. Assembly and release:
   • Association with lipid droplets
   • Virions assembled and released through the secretory pathway
   • Association with lipoproteins (forming “lipoviroparticles”)

Immune Response and Liver Injury

Innate Immune Response

• Pattern recognition receptors:
  • RIG-I, TLR3, and other PRRs detect viral RNA
  • Activate signaling cascades leading to interferon production
• Type I and III interferons:
  • First line of defense
  • Induce interferon-stimulated genes (ISGs) with antiviral properties
• Natural killer (NK) cells:
  • Recognize and kill infected hepatocytes
  • Produce cytokines that shape adaptive immune response
• Viral evasion strategies:
  • NS3/4A protease cleaves MAVS and TRIF to block interferon production
  • Core and NS5A proteins interfere with interferon signaling
  • E2 protein inhibits NK cell function

Adaptive Immune Response

• Humoral immunity:
  • Anti-HCV antibodies develop but often fail to neutralize the virus
  • High rate of viral mutations leads to antibody escape
• Cell-mediated immunity:
  • CD8+ T cells: Critical for viral clearance in acute infection
  • CD4+ T helper cells: Support CD8+ T cell and B cell functions
  • T cell failure in chronic infection: Exhaustion, anergy, altered function
• Factors affecting immune response outcome:
  • Genetic factors (HLA type, IL28B polymorphism)
  • Viral factors (genotype, viral load, quasispecies diversity)
  • Host factors (age, sex, comorbidities)

Mechanisms of Liver Injury

• Direct cytopathic effects:
  • Generally limited compared to immune-mediated damage
  • Some viral proteins (core, NS5A) may cause steatosis and oxidative stress
• Immune-mediated injury:
  • CD8+ T cell-mediated killing of infected hepatocytes
  • Cytokine-induced inflammation
  • Activation of inflammatory pathways
• Continuous cycle of hepatocyte damage and repair

Fibrosis and Cirrhosis

• Hepatic stellate cell activation:
  • Key event in fibrogenesis
  • Transformation from lipid-storing cells to myofibroblast-like cells
• Fibrogenic stimuli:
  • Proinflammatory cytokines (TGF-β, PDGF, TNF-α)
  • Oxidative stress
  • Direct effects of viral proteins
• Extracellular matrix deposition: Predominantly collagen types I and III
• Progressive fibrosis:
  • Periportal fibrosis → bridging fibrosis → cirrhosis
  • Distortion of liver architecture and vascular structures
  • Impaired hepatocyte function
  • Portal hypertension development
• Factors accelerating fibrosis:
  • Alcohol consumption
  • Coinfection with HIV or HBV
  • Fatty liver disease
  • Older age at infection
  • Male sex
  • Immunosuppression

Hepatocellular Carcinoma Pathogenesis

• Indirect mechanisms (predominant):
  • Chronic inflammation and regeneration
  • Oxidative stress and DNA damage
  • Fibrosis and cirrhosis
• Direct mechanisms:
  • Core protein: Alters cell proliferation, apoptosis, and signaling pathways
  • NS3 and NS5A proteins: Interfere with tumor suppressor functions
  • No integration into host genome (unlike HBV)
• Molecular pathways affected:
  • Wnt/β-catenin signaling
  • p53 pathway
  • Insulin/IGF signaling
  • Retinoid signaling

Pathogenesis of Extrahepatic Manifestations

Mixed Cryoglobulinemia

• Mechanism:
  • B-cell proliferation and autoantibody production (RF+)
  • Formation of immune complexes containing HCV, anti-HCV, and RF
  • Deposition in small vessels causing vasculitis
• Clinical manifestations: Purpura, arthralgia, glomerulonephritis, neuropathy

Lymphoproliferative Disorders

• Mechanism:
  • Chronic B-cell stimulation
  • Inhibition of B-cell apoptosis
  • Genetic alterations (bcl-2 rearrangements)
• Common types: Marginal zone lymphoma, diffuse large B-cell lymphoma

Renal Disease

• Mechanism:
  • Immune complex deposition in glomeruli
  • Direct viral infection of renal cells
• Manifestations: Membranoproliferative glomerulonephritis, membranous nephropathy

Insulin Resistance and Diabetes

• Mechanism:
  • Direct effect of viral proteins on insulin signaling
  • Proinflammatory cytokines interfering with insulin action
  • Hepatic steatosis

Physical Examination

The physical examination in patients with hepatitis C can vary widely depending on the stage of disease. Early chronic HCV infection typically has minimal or no physical findings, while advanced disease may show signs of chronic liver disease and portal hypertension.

General Appearance and Vital Signs

• Early/compensated disease: Often normal appearance
• Advanced disease: Cachexia, muscle wasting, jaundice
• Vital signs:
  • Usually normal in early disease
  • Tachycardia may be present in decompensated cirrhosis
  • Fever generally absent unless concurrent infection

Signs of Chronic Liver Disease

• Skin findings:
  • Jaundice: Yellow discoloration of sclera, mucous membranes, and skin
  • Spider angiomata: Vascular lesions with central arteriole and radiating vessels
  • Palmar erythema: Redness of palms, especially thenar and hypothenar eminences
  • Paper-money skin: Diffuse exfoliative skin changes
  • Terry’s nails: White nails with distal pink band
  • Dupuytren’s contracture: Palmar fascia fibrosis and contracture
• Head and neck:
  • Scleral icterus: Often the earliest sign of jaundice
  • Parotid enlargement: Bilateral, non-tender
  • Fetor hepaticus: Sweet, musty breath odor (advanced disease)
  • Kayser-Fleischer rings: Not seen in HCV (characteristic of Wilson’s disease)

Abdominal Examination

• Inspection:
  • Abdominal distension (ascites)
  • Visible venous pattern (caput medusae in severe portal hypertension)
  • Umbilical hernia (with ascites)
• Palpation:
  • Liver: Size and consistency vary with disease stage
    • Early disease: Normal or mildly enlarged, smooth
    • Cirrhosis: May be enlarged or shrunken, firm, nodular
    • Decompensated cirrhosis: Often small and difficult to palpate due to ascites
  • Spleen: Splenomegaly suggests portal hypertension
  • Ascites: Shifting dullness, fluid wave

Signs of Hepatic Decompensation

• Ascites: Fluid accumulation in peritoneal cavity
• Peripheral edema: Due to hypoalbuminemia and altered hemodynamics
• Hepatic encephalopathy:
  • Altered mental status, ranging from subtle to coma
  • Asterixis (“flapping tremor”): Brief, arrhythmic lapses in voluntary muscle contraction
  • Constructional apraxia: Inability to draw simple figures
  • Hyperreflexia or hyporeflexia
• Portal hypertensive bleeding:
  • Hematemesis or melena (from variceal bleeding)
  • Pallor, tachycardia, hypotension if acute bleeding